

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email editorial.bmjopen@bmj.com

BMJ Open

Effects of photobiomodulation therapy in patients with chronic non-specific low back pain: protocol for a randomized placebo-controlled trial

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2017-017202
Article Type:	Protocol
Date Submitted by the Author:	10-Apr-2017
Complete List of Authors:	Tomazoni, Shaiane; Universidade Cidade de Sao Paulo, Masters and Doctoral Programs in Physical Therapy Costa, Lucíola; Universidade Cidade de Sao Paulo, Masters and Doctoral Programs in Physical Therapy Guimarães, Layana; Universidade Cidade de Sao Paulo, Masters and Doctoral Programs in Physical Therapy Araujo, Amanda; Universidade Cidade de Sao Paulo, Masters and Doctoral Programs in Physical Therapy Nascimento, Dafne; Universidade Cidade de Sao Paulo, Masters and Doctoral Programs in Physical Therapy Medeiros, Flavia; Universidade Cidade de Sao Paulo, Masters and Doctoral Programs in Physical Therapy Avanzi, Marina; Universidade Cidade de Sao Paulo, Masters and Doctoral Programs in Physical Therapy Costa, Leonardo; Universidade Cidade de Sao Paulo, Masters and Doctoral Programs in Physical Therapy
Primary Subject Heading:	Evidence based practice
Secondary Subject Heading:	Rehabilitation medicine
Keywords:	chronic low back pain, photobiomodulation therapy, low-level laser therapy, LLLT, PBMT

SCHOLARONE™
Manuscripts

1
2
3 **Effects of photobiomodulation therapy in patients with chronic non-specific low back**
4 **pain: protocol for a randomized placebo-controlled trial**
5
6
7

8 Shaiane Silva Tomazoni^{1*}, Lucíola da Cunha Menezes Costa¹, Layana de Souza Guimarães¹,
9 Amanda Costa Araujo¹, Dafne Port Nascimento¹, Flavia Cordeiro Medeiros¹, Marina
10 Athayde Avanzi¹ and Leonardo Oliveira Pena Costa¹
11
12

13
14
15 1. Masters and Doctoral Programs in Physical Therapy, Universidade Cidade de São Paulo,
16 Brazil.
17

18
19
20 **Trial registration number:** NCT03089424
21

22
23 **Funding statement:** This work was supported by FAPESP (postdoctoral scholarship of
24 Shaiane Silva Tomazoni) grant number 2016/10265-0.
25
26

27
28 ***Author for correspondence:** Shaiane Silva Tomazoni
29 Universidade Cidade de São Paulo. Rua Cesário Galeno, 448/475
30 Tatuapé, São Paulo, SP, Brazil, 05508-900.
31 e-mail: shaiane.tomazoni@gmail.com
32
33
34

35
36 **Author contributions**
37

38
39 SST and LOPC contributed to the concept and design of the study. SST and LOPC
40 established the hypothesis and wrote the original proposal. SST, LCMC, LSG, ACA, DPN,
41 FCM and LOPC contributed significantly in creating the manuscript. LCMC and LOPC
42 performed critical revisions of the manuscript. SST, LCMC, LSG and LOPC wrote the final
43 version of the manuscript. All authors read and approved the final version of the manuscript.
44
45
46
47
48

49 **Number of figures and tables:** 2 figures and 0 tables.
50

51
52
53 **Conflict of interest:** the authors declare no conflict of interest.
54
55
56
57
58
59
60

ABSTRACT

Introduction: Low back pain (LBP) is one of the largest and most frequent public health problems. LBP is highly associated with absenteeism from work and generates excessive costs for health systems. Photobiomodulation therapy (PBMT) is a frequently used non-pharmacological therapy for the treatment of musculoskeletal disorders. However, there is little high-quality scientific evidence that demonstrates the effectiveness of PBMT in the treatment of patients with chronic LBP in the short, medium, and long term. Therefore, the objective of this clinical trial is to evaluate the effects of PBMT in patients with chronic non-specific LBP in the short, medium, and long term. **Methods and analyses:** This is a prospectively registered, two-arm randomized placebo-controlled trial with blinded patients, assessors and treatment providers. One hundred and forty-eight patients with chronic non-specific LBP will be recruited. Treatment sessions will be provided 3 times a week for 4 weeks (totaling 12 sessions) with patients receiving either placebo or active PBMT. For ethical reasons, all patients, regardless of treatment allocation, will also receive an information booklet based on "The Back Book". Clinical outcomes will be measured at baseline, at the end of treatment, as well as 3, 6, and 12 months after randomization. The primary outcomes will be pain intensity and disability measured after 12 sessions of treatment. The secondary outcomes will be pain intensity and disability measured at 3, 6, and 12 months after randomization, in addition to specific disability and global perceived effect in all time points. **Ethics and dissemination:** The study was approved by the Research Ethics Committee of Universidade Cidade de São Paulo. The results will be disseminated through scientific publications and presentations at national and international scientific meetings. Clinical trial registration number: NCT03089424 (clinicaltrials.gov).

Key-words: chronic low back pain, photobiomodulation therapy, low-level laser therapy, LLLT, PBMT.

Strengths and limitations of this study:

- The present study can be considered to have high methodological quality, since it is a randomized, controlled, and prospectively registered clinical trial.
- One of the strengths of the study is that it is triple-blind, i.e., evaluators, therapists, and patients will be blinded to interventions over the course of the study.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- The sample size was calculated to provide the appropriate statistical power to detect differences in the primary outcomes of the study.
- We believe that our study does not present limitations.

For peer review only

INTRODUCTION

Low back pain (LBP) is one of the greatest and most frequent public health problems, generating high levels of absenteeism at work and excessive costs to health systems (1-3). Recently, LBP was ranked as one of the seven most frequent health problems and as the debilitating symptom that affects the world's population for the largest number of years (4). It is estimated that about 12% of the world's population suffers from LBP (5). The prognosis of this condition is directly related to the duration of symptoms, with less favorable prognoses in patients with chronic LBP (i.e. with a duration of symptoms longer than three months) (6-10). Therefore, the ideal treatment for chronic LBP represents a significant challenge, since there are no treatments that truly minimize the intensity of symptoms. However, several interventions are effective in reducing pain and disability resulting from LBP in the long term (11).

The existing treatments for LBP can be divided into three categories: 1) pharmacological therapies, which trigger several adverse effects with prolonged use (12-14); 2) non-pharmacological therapies, which minimize undesirable effects and are moderately effective in LBP (15); and surgery, used only when conservative treatment is not efficient (16). Several therapies can be used to treat LBP by controlling symptoms, minimizing disability, and improving the patients' quality of life (17).

Photobiomodulation therapy (PBMT) is a non-pharmacological intervention often used in the treatment of musculoskeletal disorders such as LBP (18-21). PBMT consists in applying a non-ionized form of light, which includes laser (light amplification by stimulated emission of radiation), LED (light-emitting diodes), and other lights with a broader spectrum ranging from visible to infrared (22).

Evidence from recent years (18, 23-30) suggests that PBMT triggers positive physiological effects, such as increased microcirculation (31), increased ATP synthesis, stimulation of the mitochondrial respiratory chain (32, 33), stimulation of mitochondrial function (34), and factors that may influence the metabolism of various pathologies. In addition, there is evidence that PBMT reduces the release of reactive oxygen species (ROS) and creatine kinase (CK) activity, in addition to increasing the production of antioxidants and heat shock proteins (35, 36).

Studies have shown the effects of PBMT on LBP. Basford et al. (18) and Gur et al. (19) observed that PBMT appears to be effective in reducing pain and disability triggered by this disorder, while Konstantinovic et al. (20) and Vallone et al. (21) found that PBMT

1
2
3 combined with nonsteroidal anti-inflammatory drugs (NSAIDs) and exercise were efficient
4 in reducing chronic LBP. In a recent systematic review with meta-analysis, Glazov et al. (37)
5 found a clinically significant reduction in chronic LBP in patients treated with PBMT,
6 although a reliable conclusion was hindered by the high heterogeneity in the parameters of
7 therapy application.
8
9

10
11 Therefore, in spite of the positive results obtained in the aforementioned studies in
12 favor of PBMT, some factors warrant further investigation with high-quality studies on the
13 effects of PBMT applied in isolation in LBP and the ideal parameters of application. Finally
14 there is no placebo-controlled trial that investigated the true efficacy of PBMT in patients
15 with LBP. In view of these issues, the objectives of this study are: 1) to evaluate the short-
16 term effects of PBMT on pain intensity and disability (primary outcomes) in chronic non-
17 specific LBP and 2) to evaluate the medium- and long-term effects of PBMT on pain
18 intensity and general disability (primary outcomes) as well as the short-, medium-, and long-
19 term effects on specific disability and global perceived effect (secondary outcomes) in
20 patients with chronic nonspecific LBP.
21
22
23
24
25
26
27
28

29 **METHODS AND ANALYSES**

30 **Design**

31
32
33 A randomized, triple-blinded (patients, therapists, and outcome assessors), placebo-
34 controlled trial will be performed. The protocol of this study has been prospectively
35 registered on Clinicaltrials.gov (NCT03089424).
36
37
38
39
40
41
42

43 **Location**

44
45
46 The study will be conducted at the Center for Excellence in Clinical Research in
47 Physiotherapy of our institution.
48
49

50 **Eligibility criteria**

51
52 The study assessors will determine whether or not patients will be eligible to
53 participate in the study based on patient history and clinical examination.
54
55

56
57 Inclusion criteria:
58
59
60

- Patients with non-specific chronic LBP, defined as pain or discomfort between the costal margins and inferior gluteal folds with or without referred pain to the lower limbs;
- Persistent LBP for at least 3 months (38);
- Aged between 18 and 65 years;
- Both genders.

Exclusion criteria:

- Patients with severe skin diseases;
- Patients with LBP associated with nerve root compromise (measured by clinical examination of dermatomes, myotomes, and reflexes);
- Serious spinal pathologies such as fractures, tumors, inflammatory and infectious diseases;
- Decompensated heart disease or metabolic disorders;
- Previous spinal surgery;
- Pregnancy.

Interventions

For ethical reasons, on the first day of treatment, all groups will receive an information booklet on LBP called "The Back Book" (39) based on the recommendations of the European Guidelines (40, 41). The booklet can be accessed freely via internet and it has been translated into Portuguese by our research team. At each treatment session, patients will receive further explanations on the contents of the booklet. There is consistent evidence that *The Back Book* is useful for patients with LBP (42) and it has been used in clinical trials conducted by our research group (43, 44).

Patients will then be randomly allocated to two groups to be submitted to the following interventions:

1. Active PBMT Group: The PBMT will be performed using the Multi Radiance Medical™ Super Pulsed Laser MR4™ console (Solon, OH, USA), with the SE25 (emitter with an area of 4 cm²) and LaserShower (emitter with an area of 20 cm²) cluster probes as emitters. Nine sites will be irradiated on the patient's lumbar region: 3 central sites on top of the spinous processes (between T11 and T12, L2 and L3, L5 and S1), using the SE25 (3000 Hz of frequency, 3 minutes of irradiation per site, 24.75 J per site, a totalizing 74.25 J

1
2
3 irradiated from SE25); in the same direction, but laterally, 3 sites on the left and 3 on the
4 right (on the paravertebral muscles), using the LaserShower (1000 Hz of frequency, 3
5 minutes of irradiation per site, 24.30 J per site, a total of 145.80 J irradiated from
6 LaserShower). Patients will be treated during 12 sessions over a period of four weeks (three
7 sessions/week). At each treatment session, patients will receive a total dose of 220.05 J. At
8 the end of the 12 treatments sessions, patients will receive a total dose of 2640.60 J.

9
10
11
12
13 The total treatment time will be 27 minutes per patient. This PBMT application
14 protocol was based on the study of Leal Junior et al. (45). Figure 1 shows the PBMT
15 irradiation sites.
16
17

18
19
20 << Figure 1 >>
21
22

23
24 2. Placebo PBMT Group: The placebo PBMT will be performed using the Multi
25 Radiance Medical™ Super Pulsed Laser MR4™ console (Solon, OH, USA), with the SE25
26 (emitter with an area of 4 cm²) and LaserShower (emitter with an area of 20 cm²) cluster
27 probes as emitters. Nine sites will be irradiated on the patient's lumbar region: 3 central sites
28 on top of the spinous processes (between T11 and T12, L2 and L3, L5 and S1), using the
29 SE25 (without any dose, 0 J); in the same direction, but laterally, 3 sites on the left and 3 on
30 the right (on the paravertebral muscles), using the LaserShower (without any dose, 0 J).
31 Patients will be treated during 12 sessions over a period of four weeks (three sessions/week).
32 At each treatment session, patients will receive a total dose of 0 J. At the end of the 12
33 treatments sessions, patients will receive a total dose of 0 J. The placebo mode simulates the
34 pragmatism of clinical practice and increases the credibility of the use of the equipment in
35 relation to the treated patients. The placebo technique has already been widely used in other
36 studies with patients with LBP (44, 46-51), as well as in studies using PBMT (52-54).
37
38
39
40
41
42
43
44

45 Patients will undergo treatment (active PBMT or placebo), according to prior
46 randomization, 3 times a week for 4 consecutive weeks, totaling 12 therapy sessions.
47

48 The CONSORT flowchart summarizing experimental procedures and patients are
49 shown in figure 2.
50
51

52
53 << Figure 2 >>
54
55

56 Outcomes

57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Primary and secondary outcomes of the study will be obtained at baseline, at the end of treatment (4 weeks), and 3, 6, and 12 months after randomization. These outcomes will be collected by an assessor who will not be aware of patient allocation to their treatment groups.

The primary outcomes of the study will be:

- Pain intensity measured by the Pain Numerical Rating Scale (55). Pain Numerical Rating Scale evaluates pain intensity levels perceived by the patient on an 11-point scale ranging from 0 to 10, with 0 being "no pain" and 10 "the worst possible pain" (55). Patients will be instructed to score the level of pain intensity based on the last 7 days.
- Disability associated with LBP, as measured by the Roland-Morris Disability Questionnaire (56, 57). The questionnaire consists of 24 items that describe situations that patients may have difficulty performing on a daily basis due to LBP. The greater the number of affirmative answers is, the higher the level of functional disability associated with LBP (55, 57). Patients will be instructed to answer according to their condition on the day of administration of the questionnaire.

The secondary outcomes of the study will be:

- Specific disability, as measured by the Patient-Specific Functional Scale (55). The Patient-Specific Functional Scale is global and can be used for any part of the body. The measurement is done on an 11-point Likert scale for each activity, and the higher the average score is (ranging from 0 and 10 points), the better the patient's ability to perform the activities. The patients will be asked to identify up to three activities that they consider they are incapable of performing or that they have some difficulty performing (55, 58, 59).
- Global perceived effect as measured by the Global Perceived Effect Scale (55). Global Perceived Effect Scale is an 11-point Likert scale, ranging from -5 to +5, that compares the patient's current condition to the onset of symptoms (55). Positive scores represent improvement, while the negative scores represent worsening in relation to the onset of symptoms. Values closer to 5 mean greater intensity of this perception (55).

Sample size

1
2
3 The sample calculation of the study was performed to detect a 1-point difference for
4 the outcome pain intensity (as measured by the Pain Numerical Rating Scale) (55), with an
5 estimated standard deviation of 1.84 points and 4 points for the outcome disability associated
6 with LBP (measured by the Roland-Morris Disability Questionnaire) (56, 57), with an
7 estimated standard deviation of 4.9 points. A statistical power of 80% was considered for the
8 two outcomes, with α of 5% and a possible sample loss of up to 15%. Therefore, a total of
9 148 patients will be required for the study.
10
11
12
13

14 15 16 **Recruitment**

17
18
19 Patients seeking treatment for chronic LBP will be recruited at primary or secondary
20 health services.
21
22

23 24 **Randomization**

25
26
27 Prior to initiation of treatment, patients will be randomized into their respective
28 intervention groups. The randomization will be generated by a computer program (Excel
29 Office 2010) and performed by a participating researcher not involved with the recruitment
30 or evaluation of patients. This same researcher will be responsible for programming the
31 PBMT device according to the result of the randomization. The PBMT device used in the
32 present study will make the same sounds regardless of the programmed dose and mode
33 (active PBMT or placebo PBMT). This researcher will be instructed not to disclose the
34 programmed intervention to the therapist or any of the patients and other researchers
35 involved in the study until its completion. Patient and therapist will be blinded throughout
36 the treatment. Concealed allocation will be achieved through the use of sequentially
37 numbered, sealed, and opaque envelopes.
38
39
40
41
42
43
44
45
46
47

48 **Data collection**

49
50 The patients will be welcomed by the study's blinded assessor who will determine
51 whether they will be eligible to participate in the study. Subsequently, a file will be
52 completed with the patient's sociodemographic data and clinical history. Next, the primary
53 outcomes and the secondary outcomes of the study will be collected. Then, all eligible
54 patients will be randomized and allocated into two treatment groups: active PBMT or
55 placebo PBMT. At the end of the 12 treatment sessions, the primary and secondary outcomes
56
57
58
59
60

1
2
3 of the study participants will be reassessed by the same evaluator who performed the
4 baseline assessment. The 3, 6, and 12-month follow-ups will be performed by telephone by
5 the same evaluator who carried out the other evaluations.
6
7

8 9 **Statistical Analysis**

10
11
12 The statistical analysis will be conducted following the principles of intention-to-treat
13 analysis (60). The normality of the data will be tested by visual inspection of histograms and
14 the characterization of the participants will be calculated using descriptive statistical tests.
15 The between-group differences (treatment effects) and their respective 95% confidence
16 intervals will be calculated by using mixed linear models (61) using the group-by-time
17 interaction terms. The analyses will be performed using SPSS version 19.
18
19
20
21
22

23 24 **Ethics**

25
26
27 The present study was approved by the Research Ethics Committee of Universidade
28 Cidade de São Paulo (UNICID) under number 1.964.094. All patients eligible for the study
29 will be informed of the objectives and will be required to complete the Informed Consent
30 Form, as determined by Brazilian National Health Council Resolution 196/96.
31
32
33

34 35 **Dissemination**

36
37
38 The study will be disseminated through publication in peer-reviewed international
39 journals, as well as presentations at national and international conferences.
40
41
42

43 44 **Discussion**

45
46
47 Chronic LBP is a condition that is often associated with disability, emotional
48 alterations, and absenteeism from work (8). Since chronic LBP is very prevalent (11), it has
49 a great financial impact, generating high costs, both direct and indirect (62). This fact
50 demonstrates the importance of the constant investigation of more suitable treatments for
51 LBP, aiming at the well-being of the patient and the reduction of expenses for health
52 systems.
53
54
55
56
57
58
59
60

1
2
3 PBMT is one of the interventions recommended for the treatment of chronic LBP
4 (63), however, it is a relatively recent therapy given that the first clinical trial investigating
5 its effects on LBP was published in 1999 (18). Since then, some studies have demonstrated
6 the efficacy of PBMT in LBP (19-21). Nevertheless, there are still issues to be clarified
7 about its efficacy, as there are no high-quality methodological studies that test PBMT versus
8 placebo in LBP patients.
9

10
11
12
13 It is extremely important to carry out studies with high methodological quality aimed
14 at contributing to a better understanding of the effects of PBMT on LBP. Only then will it be
15 possible to determine whether PBMT can be used as one of the treatments of choice for LBP.
16 If the effectiveness of PBMT in LBP is confirmed, it could be used as an alternative method
17 to NSAIDs or opioids, for example, since it causes similar or superior effects to these drugs,
18 shown in other chronic musculoskeletal disorders (64, 65), without the presence of known
19 adverse effects at present. We believe that, by providing relevant and compelling
20 information about PBMT, we will contribute to a safer and more effective clinical practice.
21

22
23
24
25
26 The present study can be considered to have high methodological quality, since it is a
27 randomized, controlled, and prospectively registered clinical trial. In addition, one of the
28 strengths of the study is that it is triple-blind, i.e., evaluators, therapists, and patients will be
29 blinded to interventions over the course of the study. Finally, the sample size was calculated
30 to provide the appropriate statistical power to detect differences in the primary outcomes of
31 the study. Thus, we believe that this study will contribute to the evidence-based practice of
32 PBMT in patients with LBP.
33
34
35
36
37
38

39 **Conflict of interest**

40
41 The authors declare no conflict of interest.
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

References:

1. Tulder MV. Chapter 1. European guidelines. *Eur Spine J* 2006;15:134-35.
2. Academia Americana De Cirurgiões Ortopédicos (American Academy Of Orthopaedic Surgeons). *US Bone and Joint Decade - The Burden of Musculoskeletal Diseases in the United States*. Rosemont, IL, USA, 2008.
3. Dagenais S, Caro J, Haldeman SA. systematic review of low back pain cost of illness studies in the United States and internationally. *Spine J*. 2008;8:8-20.
4. Murray CJ, Lopez AD. Measuring the global burden of disease. *N Engl J Med*. 2013;369:448-457.
5. Hoy D, Bain C, Williams G, March L, Brooks P, Blyth F, et al. A systematic review of the global prevalence of low back pain. *Arthritis Rheum*. 2012;64:2028-37.
6. Henschke N, Maher CG, Refshauge KM, Herbert RD, Cumming RG, Bleasel J, et al. Prognosis in patients with recent onset low back pain in Australian primary care: inception cohort study. *BMJ*. 2008;337:a171.
7. Costa Lda C, Maher CG, Mcauley JH, Hancock MJ, Herbert RD, Refshauge KM, et al. Prognosis for patients with chronic low back pain: inception cohort study. *BMJ*. 2009;339:b3829.
8. Da C Menezes Costa L, Maher CG, Hancock MJ, Mcauley JH, Herbert RD, Costa LO. The prognosis of acute and persistent low-back pain: a meta-analysis. *CMAJ*. 2012;184:E613-624.
9. Beattie PF, Silfies SP, Jordon M. The evolving role of physical therapists in the long-term management of chronic low back pain: longitudinal care using assisted self-management strategies. *Braz J Phys Ther* 2016;20:580-91.
10. Medeiros FC, Costa LO, Added MA, Salomão EC, Costa LD. Serial Monitoring of Patients With Chronic Low Back Pain During Physical Therapy Treatment Using the STarT Back Screening Tool. *J Orthop Sports Phys Ther*. 2017;29:1-32. [Epub ahead of print]
11. Maher C, Underwood M, Buchbinder R. Non-specific low back pain. *Lancet*. 2017;389:736-47.
12. Bjordal JM, Ljunggren AE, Klovning A, Slørdal L. Non-steroidal anti-inflammatory drugs, including cyclo-oxygenase-2 inhibitors, in osteoarthritic knee pain: meta-analysis of randomised placebo controlled trials. *BMJ*. 2004;329:1317.
13. Chou R. Pharmacological management of low back pain. *Drugs*. 2010;70:387-402.
14. Dagenais S, Tricco AC, Haldeman S. Synthesis of recommendations for the assessment and management of low back pain from recent clinical practice guidelines. *Spine J*. 2010;10:514-29.

- 1
2
3 15. Van Middelkoop M, Rubinstein SM, Kuijpers T, Verhagen AP, Ostelo R, Koes BW, et
4 al. A systematic review on the effectiveness of physical and rehabilitation interventions for
5 chronic non-specific low back pain. *Eur Spine J.* 2011;20:19-39.
6
7 16. Bertagnoli R. Disc surgery in motion. *SpineLine.* 2004;5:23-28.
8
9 17. Sanders SH, Rucker KS, Anderson KO, Harden RN, Jackson KW, Vicente PJ, et al.
10 Clinical practice guidelines for chronic non-malignant pain syndrome patients. *J Back*
11 *Musculoskelet Rehabil.* 1995;5:115-20.
12
13 18. Basford JR, Sheffield CG, Harmsen WS. Laser therapy: a randomized, controlled trial of
14 the effects of low-intensity Nd:YAG laser irradiation on musculoskeletal back pain. *Arch*
15 *Phys Med Rehabil.* 1999;80:647-52.
16
17 19. Gur A, Karakoc M, Cevik R, Nas K, Sarac AJ, Karakoc M. Efficacy of low power laser
18 therapy and exercise on pain and functions in chronic low back pain. *Lasers Surg Med.*
19 2003;32:233-38.
20
21 20. Konstantinovic LM, Kanjuh ZM, Milovanovic AN, Cutovic MR, Djurovic AG, Savic
22 VG, et al. Acute low back pain with radiculopathy: a double-blind, randomized, placebo-
23 controlled study. *Photomed Laser Surg.* 2010;28:553-60.
24
25 21. Vallone F, Benedicenti S, Sorrenti E, Schiavetti I, Angiero F. Effect of diode laser in the
26 treatment of patients with nonspecific chronic low back pain: a randomized controlled trial.
27 *Photomed Laser Surg.* 2014;32:490-94.
28
29 22. Anders JJ, Lanzafame RJ, Arany PR. Low-level light/laser therapy versus
30 photobiomodulation therapy. *Photomed Laser Surg.* 2015;33:183-184.
31
32 23. Walker BF. The prevalence of low back pain: a systematic review of the literature from
33 1966 to 1998. *J Spinal Disord.* 2000;13:205-17.
34
35 24. Rochkind S, Nissan M, Alon M, Shamir M, Salame K. Effects of laser irradiation on the
36 spinal cord for the regeneration of crushed peripheral nerve in rats. *Lasers Surg Med.*
37 2001;28:216-19.
38
39 25. Ozdemir F, Birtane M, Kokino S. The clinical efficacy of low-power laser therapy on
40 pain and function in cervical osteoarthritis. *Clin Rheumatol.* 2001;20:181-84.
41
42 26. Bjordal JM, Lopes-Martins RA, Iversen VV. A randomised, placebo controlled trial of
43 low level laser therapy for activated Achilles tendinitis with microdialysis measurement of
44 peritendinous prostaglandin E2 concentrations. *Br J Sports Med.* 2006;40:76-80.
45
46 27. Chow RT, Heller GZ, Barnsley L. The effect of 300 mW, 830 nm laser on chronic neck
47 pain: a double-blind, randomized, placebo-controlled study. *Pain.* 2006;124:1-2.
48
49 28. Rochkind S, Leider-Trejo L, Nissan M, Shamir MH, Kharenko O, Alon M. Efficacy of
50 780-nm laser phototherapy on peripheral nerve regeneration after neurotube reconstruction
51 procedure (double-blind randomized study). *Photomed. Laser Surg.* 2007;25:137-43.
52
53
54
55
56
57
58
59
60

- 1
2
3 29. Leal Junior EC, Lopes-Martins RA, Baroni BM, De Marchi T, Taufer D, Manfro DS, et
4 al. Effect of 830 nm low-level laser therapy applied before high-intensity exercises on
5 skeletal muscle recovery in athletes. *Lasers Med Sci.* 2009;24:857-63.
6
7
8 30. Zivin JA, Albers GW, Bornstein N, Chippendale T, Dahlof B, Devlin T, et al.
9 Effectiveness and safety of transcranial laser therapy for acute ischemic stroke. *Stroke.*
10 2009;40:1359-64.
11
12 31. Tullberg M, Alstergren PJ, Ernberg MM. Effects of low-power laser exposure on
13 masseter muscle pain and microcirculation. *Pain.* 2003;105:89-96.
14
15 32. Silveira PC, Silva LA, Fraga DB, Freitas TP, Streck EL, Pinho R. Evaluation of
16 mitochondrial respiratory chain activity in muscle healing by low-level laser therapy. *J*
17 *Photochem Photobiol B.* 2009;4:89-92
18
19 33. Albuquerque-Pontes GM, Vieira RP, Tomazoni SS, Caires CO, Nemeth V, Vanin AA, et
20 al. Effect of pre-irradiation with different doses, wavelengths, and application intervals of
21 low-level laser therapy on cytochrome c oxidase activity in intact skeletal muscle of rats.
22 *Lasers Med Sci.* 2015;30:59-66.
23
24 34. Xu X, Zhao X, Liu TC, Pan H. Low-intensity laser irradiation improves the
25 mitochondrial dysfunction of C2C12 induced by electrical stimulation. *Photomed Laser*
26 *Surg.* 2008;26:197-202.
27
28 35. Avni D, Levkovitz S, Maltz L, Oron U. Protection of skeletal muscles from ischemic
29 injury: low-level laser therapy increases antioxidant activity. *Photomed Laser Surg.*
30 2005;23:273-277
31
32 36. Rizzi CF, Mauriz JL, Freitas Corrêa DS, Moreira AJ, Zettler CG, Filippin LI, et al.
33 Effects of low-level laser therapy (LLLT) on the nuclear factor (NF)-kappaB signaling
34 pathway in traumatized muscle. *Lasers Surg Med.* 2006;38:704-13.
35
36 37. Glazov G, Yelland M, Emery J. Low-level laser therapy for chronic non-specific low
37 back pain: a meta-analysis of randomised controlled trials. *Acupunct Med.* 2016;34:328-341.
38
39 38. Airaksinen O, Brox JI, Cedraschi C, Hildebrandt J, Klüber-Moffett J, Kovacs F, et al.
40 Chapter 4. European guidelines for the management of chronic nonspecific low back pain.
41 *Eur Spine J.* 2006;15Suppl2:192-300.
42
43 39. Manchester MR, Glasgow GW, York JKM, Huddersfield KB, Salford CM, Southampton
44 TC. The Back Book. Clinical Guidelines for the Management of Acute Low Back Pain.
45 2002;1-28.
46
47 40. Van Tulder M, Becker A, Bekkering T, Breen A, Del Real MT, Hutchinson A, et al.
48 Chapter 3. European guidelines for the management of acute nonspecific low back pain in
49 primary care. *Eur Spine J.* 2006;15Suppl2:S169-191.
50
51 41. Delitto A, George SZ, Van Dillen LR, Whitman JM, Sowa G, Shekelle P, et al.
52 Orthopaedic Section of the American Physical Therapy Association. Low back pain. *J*
53 *Orthop Sports Phys Ther.* 2012;42: A1-57.
54
55
56
57
58
59
60

- 1
2
3 42. Engers A, Jellema P, Wensing M, Van Der Windt DA, Grol R, Van Tulder MW.
4 Individual patient education for low back pain. *Cochrane Database Syst Rev.*
5 2008;23:CD004057.
6
7 43. Garcia AN, Costa L Da C, Hancock MJ, De Almeida MO, De Souza FS, Costa LO.
8 Efficacy of the McKenzie method in patients with chronic nonspecific low back pain: a
9 protocol of randomized placebo-controlled trial. *Phys Ther.* 2015;95:267-273.
10
11 44. Garcia AN, Hancock M, Costa LCM, De Souza, FS, Gomes, GVFO, Almeida, MO, et al.
12 Efficacy of the mechanical diagnosis and therapy in patients with chronic nonspecific low
13 back pain: a randomized placebo controlled trial. 2017; [in press]
14
15 45. Leal-Junior EC, Johnson DS, Saltmarche A, Demchak T. Adjunctive use of combination
16 of super-pulsed laser and light-emitting diodes phototherapy on nonspecific knee pain:
17 double-blinded randomized placebo-controlled trial. *Lasers Med Sci.* 2014;29:1839-47.
18
19 46. Costa LO, Maher CG, Latimer J, Hodges PW, Herbert RD, Refshauge KM.; et al. Motor
20 control exercise for chronic low back pain: a randomized placebo-controlled trial. *Phys Ther.*
21 2009;89:1275-86.
22
23 47. Kumar SP. Efficacy of segmental stabilization exercise for lumbar segmental instability
24 in patients with mechanical low back pain: A randomized placebo controlled crossover
25 study. *N Am J Med Sci.* 2011;3:456-461.
26
27 48. Ebadi S, Ansari NN, Naghdi S, Jalaei S, Sadat M, Bagheri H, et al. The effect of
28 continuous ultrasound on chronic non-specific low back pain: a single blind placebo-
29 controlled randomized trial. *BMC Musculoskelet Disord.* 2012;13:192.
30
31 49. Balthazard P, De Goumoens P, Rivier G, Demeulenaere P, Ballabeni P, Dériaz O.
32 Manual therapy followed by specific active exercises versus a placebo followed by specific
33 active exercises on the improvement of functional disability in patients with chronic non
34 specific low back pain: a randomized controlled trial. *BMC Musculoskelet Disord.*
35 2012;13:162.
36
37 50. Parreira Pdo C, Costa Lda C, Takahashi R, Hespanhol Junior LC, Luz Junior MA, Silva
38 TM, Costa LO. Kinesio taping to generate skin convolutions is not better than sham taping
39 for people with chronic non-specific low back pain: a randomised trial. *J Physiother.*
40 2014;60:90-6.
41
42 51. Luz Júnior MA, Sousa MV, Neves LA, Cezar AA, Costa LO. Kinesio Taping® is not
43 better than placebo in reducing pain and disability in patients with chronic non-specific low
44 back pain: a randomized controlled trial. *Braz J Phys Ther.* 2015;19:482-90.
45
46 52. Antonialli FC, De Marchi T, Tomazoni SS, Vanin AA, Dos Santos Grandinetti V, De
47 Paiva PR, et al. Phototherapy in skeletal muscle performance and recovery after exercise:
48 effect of combination of super-pulsed laser and light-emitting diodes. *Lasers Med Sci.*
49 2014;29:1967-76.
50
51 53. Grandinetti V Dos S, Miranda EF, Johnson DS, De Paiva PR, Tomazoni SS, Vanin AA,
52 et al. The thermal impact of phototherapy with concurrent super-pulsed lasers and red and
53
54
55
56
57
58
59
60

1
2
3 infrared LEDs on human skin. *Lasers Med Sci.* 2015;30:1575-81.

4
5 54. Miranda EF, De Oliveira LV, Antonialli FC, Vanin AA, De Carvalho PdeT, Leal-Junior
6 EC. Phototherapy with combination of super-pulsed laser and light-emitting diodes is
7 beneficial in improvement of muscular performance (strength and muscular endurance),
8 dyspnea, and fatigue sensation in patients with chronic obstructive pulmonary disease.
9 *Lasers Med Sci.* 2015;30:437-43.

10
11 55. Costa LO, Maher CG, Latimer J, Ferreira PH, Ferreira ML, Pozzi GC, et al. Clinimetric
12 testing of three self-report outcome measures for low back pain patients in Brazil: which one
13 is the best? *Spine (Phila Pa 1976).* 2008;33:2459-63.

14
15 56. Nusbaum L, Natour J, Ferraz MB, Goldenberg J. Translation, adaptation and validation
16 of the Roland-Morris questionnaire--Brazil Roland-Morris. *Braz J Med Biol Res.*
17 2001;34:203-210.

18
19 57. Costa LO, Maher CG, Latimer J, Ferreira PH, Pozzi GC, Ribeiro RN. Psychometric
20 characteristics of the Brazilian-Portuguese versions of the Functional Rating Index and the
21 Roland Morris Disability Questionnaire. *Spine (Phila Pa 1976).* 2007;32:1902-07.

22
23 58. Chatman AB, Hyams SP, Neel JM, Binkley JM, Stratford PW, Schomberg A, et al. The
24 Patient-Specific Functional Scale: measurement properties in patients with knee dysfunction.
25 *Phys Ther.* 1997;77:820-29.

26
27 59. Pengel LH, Refshauge KM, Maher CG. Responsiveness of pain, disability, and physical
28 impairment outcomes in patients with low back pain. *Spine (Phila Pa 1976).* 2004;29:879-83.

29
30 60. Elkins MR, Moseley AM. Intention-to-treat analysis. *J Physiother.* 2015;61:165-67.

31
32 61. Twisk JWR. *Applied Longitudinal Data Analysis for Epidemiology: A Practical Guide*
33 ISBN: 0521819768, 9780511061608; 2003.

34
35 62. Walker BF, Muller R, Grant WD. Low back pain in Australia adults: the economic
36 burden. *Asia Pac J Public Health.* 2003;15:79-87.

37
38 63. Qaseem A, Wilt TJ, Mclean RM, Forciea MA. Clinical Guidelines Committee of the
39 American College of Physicians. Noninvasive Treatments for Acute, Subacute, and Chronic
40 Low Back Pain: A Clinical Practice Guideline From the American College of Physicians.
41 *Ann Intern Med.* 2017;166:514-30.

42
43 64. Tomazoni SS, Leal-Junior EC, Frigo L, Pallotta RC, Teixeira S, de Almeida P, et al.
44 Isolated and combined effects of photobiomodulation therapy, topical nonsteroidal anti-
45 inflammatory drugs, and physical activity in the treatment of osteoarthritis induced by
46 papain. *J Biomed Opt.* 2016;21:108001.

47
48 65. Tomazoni SS, Leal-Junior EC, Pallotta RC, Teixeira S, De Almeida P, Lopes-Martins
49 R.Á. Effects of photobiomodulation therapy, pharmacological therapy, and physical exercise
50 as single and/or combined treatment on the inflammatory response induced by experimental
51 osteoarthritis. *Lasers Med Sci.* 2017;32:101-108.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

FIGURE LEGENDS

Figure 1. PBMT irradiation sites.

Figure 2. Flow diagram of the study.

For peer review only



Figure 1. PBMT irradiation sites.

254x190mm (72 x 72 DPI)

ew only




Figure 2. Flow diagram of the study.

197x235mm (72 x 72 DPI)



SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents*

Section/item	Item No	Description	Page Number
Administrative information			
Title	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	1
Trial registration	2a	Trial identifier and registry name. If not yet registered, name of intended registry	1
	2b	All items from the World Health Organization Trial Registration Data Set	1
Protocol version	3	Date and version identifier	1
Funding	4	Sources and types of financial, material, and other support	1
Roles and responsibilities	5a	Names, affiliations, and roles of protocol contributors	1
	5b	Name and contact information for the trial sponsor	1
	5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	1
	5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)	1
Introduction			
Background and rationale	6a	Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention	4
	6b	Explanation for choice of comparators	7
Objectives	7	Specific objectives or hypotheses	5
Trial design	8	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory)	5

Methods: Participants, interventions, and outcomes

Study setting	9	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained	5
Eligibility criteria	10	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists)	5, 6
Interventions	11a	Interventions for each group with sufficient detail to allow replication, including how and when they will be administered	6, 7
	11b	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving/worsening disease)	6, 7
	11c	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return, laboratory tests)	6, 7
	11d	Relevant concomitant care and interventions that are permitted or prohibited during the trial	6, 7
Outcomes	12	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended	7, 8
Participant timeline	13	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure)	9
Sample size	14	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations	8, 9
Recruitment	15	Strategies for achieving adequate participant enrolment to reach target sample size	9

Methods: Assignment of interventions (for controlled trials)

Allocation:

Sequence generation	16a	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions	9
---------------------	-----	--	---

1				
2	Allocation	16b	Mechanism of implementing the allocation sequence (eg, central	9
3	concealment		telephone; sequentially numbered, opaque, sealed envelopes),	
4	mechanism		describing any steps to conceal the sequence until interventions are	
5			assigned	
6				
7	Implementation	16c	Who will generate the allocation sequence, who will enrol participants,	9
8			and who will assign participants to interventions	
9				
10	Blinding	17a	Who will be blinded after assignment to interventions (eg, trial	9
11	(masking)		participants, care providers, outcome assessors, data analysts), and	
12			how	
13				
14		17b	If blinded, circumstances under which unblinding is permissible, and	9
15			procedure for revealing a participant's allocated intervention during the	
16			trial	
17				
18				

19 **Methods: Data collection, management, and analysis**

20				
21	Data collection	18a	Plans for assessment and collection of outcome, baseline, and other	8
22	methods		trial data, including any related processes to promote data quality (eg,	
23			duplicate measurements, training of assessors) and a description of	
24			study instruments (eg, questionnaires, laboratory tests) along with their	
25			reliability and validity, if known. Reference to where data collection	
26			forms can be found, if not in the protocol	
27				
28		18b	Plans to promote participant retention and complete follow-up, including	9
29			list of any outcome data to be collected for participants who discontinue	
30			or deviate from intervention protocols	
31				
32				
33	Data	19	Plans for data entry, coding, security, and storage, including any related	9
34	management		processes to promote data quality (eg, double data entry; range checks	
35			for data values). Reference to where details of data management	
36			procedures can be found, if not in the protocol	
37				
38	Statistical	20a	Statistical methods for analysing primary and secondary outcomes.	10
39	methods		Reference to where other details of the statistical analysis plan can be	
40			found, if not in the protocol	
41				
42		20b	Methods for any additional analyses (eg, subgroup and adjusted	10
43			analyses)	
44				
45		20c	Definition of analysis population relating to protocol non-adherence (eg,	10
46			as randomised analysis), and any statistical methods to handle missing	
47			data (eg, multiple imputation)	
48				
49				

50 **Methods: Monitoring**

51				
52	Data monitoring	21a	Composition of data monitoring committee (DMC); summary of its role	-
53			and reporting structure; statement of whether it is independent from the	
54			sponsor and competing interests; and reference to where further details	
55			about its charter can be found, if not in the protocol. Alternatively, an	
56			explanation of why a DMC is not needed	
57				
58				
59				
60				

1		21b	Description of any interim analyses and stopping guidelines, including	-
2			who will have access to these interim results and make the final	
3			decision to terminate the trial	
4				
5				
6	Harms	22	Plans for collecting, assessing, reporting, and managing solicited and	-
7			spontaneously reported adverse events and other unintended effects of	
8			trial interventions or trial conduct	
9				
10	Auditing	23	Frequency and procedures for auditing trial conduct, if any, and	-
11			whether the process will be independent from investigators and the	
12			sponsor	
13				
14				
15	Ethics and dissemination			
16				
17	Research ethics approval	24	Plans for seeking research ethics committee/institutional review board	10
18			(REC/IRB) approval	
19				
20	Protocol amendments	25	Plans for communicating important protocol modifications (eg, changes	-
21			to eligibility criteria, outcomes, analyses) to relevant parties (eg,	
22			investigators, REC/IRBs, trial participants, trial registries, journals,	
23			regulators)	
24				
25	Consent or assent	26a	Who will obtain informed consent or assent from potential trial	10
26			participants or authorised surrogates, and how (see Item 32)	
27				
28		26b	Additional consent provisions for collection and use of participant data	-
29			and biological specimens in ancillary studies, if applicable	
30				
31	Confidentiality	27	How personal information about potential and enrolled participants will	10
32			be collected, shared, and maintained in order to protect confidentiality	
33			before, during, and after the trial	
34				
35				
36	Declaration of interests	28	Financial and other competing interests for principal investigators for	1
37			the overall trial and each study site	
38				
39	Access to data	29	Statement of who will have access to the final trial dataset, and	10
40			disclosure of contractual agreements that limit such access for	
41			investigators	
42				
43	Ancillary and post-trial care	30	Provisions, if any, for ancillary and post-trial care, and for compensation	-
44			to those who suffer harm from trial participation	
45				
46	Dissemination policy	31a	Plans for investigators and sponsor to communicate trial results to	10
47			participants, healthcare professionals, the public, and other relevant	
48			groups (eg, via publication, reporting in results databases, or other data	
49			sharing arrangements), including any publication restrictions	
50				
51				
52		31b	Authorship eligibility guidelines and any intended use of professional	-
53			writers	
54				
55		31c	Plans, if any, for granting public access to the full protocol, participant-	10
56			level dataset, and statistical code	
57				
58				
59				
60				

Appendices

Informed consent materials	32	Model consent form and other related documentation given to participants and authorised surrogates
Biological specimens	33	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable

*It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items. Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons "[Attribution-NonCommercial-NoDerivs 3.0 Unported](#)" license.

BMJ Open

Effects of photobiomodulation therapy in patients with chronic non-specific low back pain: protocol for a randomized placebo-controlled trial

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2017-017202.R1
Article Type:	Protocol
Date Submitted by the Author:	15-Jun-2017
Complete List of Authors:	Tomazoni, Shaiane; Universidade Cidade de Sao Paulo, Masters and Doctoral Programs in Physical Therapy Costa, Lucíola; Universidade Cidade de Sao Paulo, Masters and Doctoral Programs in Physical Therapy Guimarães, Layana; Universidade Cidade de Sao Paulo, Masters and Doctoral Programs in Physical Therapy Araujo, Amanda; Universidade Cidade de Sao Paulo, Masters and Doctoral Programs in Physical Therapy Nascimento, Dafne; Universidade Cidade de Sao Paulo, Masters and Doctoral Programs in Physical Therapy Medeiros, Flavia; Universidade Cidade de Sao Paulo, Masters and Doctoral Programs in Physical Therapy Avanzi, Marina; Universidade Cidade de Sao Paulo, Masters and Doctoral Programs in Physical Therapy Costa, Leonardo; Universidade Cidade de Sao Paulo, Masters and Doctoral Programs in Physical Therapy
Primary Subject Heading:	Evidence based practice
Secondary Subject Heading:	Rehabilitation medicine
Keywords:	chronic low back pain, photobiomodulation therapy, low-level laser therapy, LLLT, PBMT

SCHOLARONE™
Manuscripts

1
2
3 **Effects of photobiomodulation therapy in patients with chronic non-specific low back**
4 **pain: protocol for a randomized placebo-controlled trial**
5
6
7

8 Shaiane Silva Tomazoni^{1*}, Lucíola da Cunha Menezes Costa¹, Layana de Souza Guimarães¹,
9 Amanda Costa Araujo¹, Dafne Port Nascimento¹, Flávia Cordeiro Medeiros¹, Marina
10 Athayde Avanzi¹ and Leonardo Oliveira Pena Costa¹
11
12
13

14 1. Masters and Doctoral Programs in Physical Therapy, Universidade Cidade de São Paulo,
15 Brazil.
16
17

18
19
20 **Trial registration number:** NCT03089424
21

22
23 **Funding statement:** This work was supported by FAPESP (postdoctoral scholarship of
24 Shaiane Silva Tomazoni) grant number 2016/10265-0.
25
26

27
28 ***Author for correspondence:** Shaiane Silva Tomazoni
29 Universidade Cidade de São Paulo. Rua Cesário Galeno, 448/475
30 Tatuapé, São Paulo, SP, Brazil, 05508-900.
31 e-mail: shaiane.tomazoni@gmail.com
32
33
34

35
36 **Number of figures and tables:** 2 figures and 1 table.
37
38

39 **Conflict of interest:** the authors declare no conflict of interest.
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

ABSTRACT

Introduction: Low back pain (LBP) is one of the largest and most frequent public health problems worldwide. Photobiomodulation therapy (PBMT) is a frequently used non-pharmacological therapy for the treatment of musculoskeletal disorders. However, there is little high-quality scientific evidence that demonstrates the effectiveness of PBMT in the treatment of patients with chronic LBP in the short, medium, and long term. Therefore, the objective of this clinical trial is to evaluate the effects of PBMT in patients with chronic non-specific LBP in the short, medium, and long term. **Methods and analyses:** This is a prospectively registered, two-arm randomized placebo-controlled trial with blinded patients, assessors and treatment providers. One hundred and forty-eight patients with chronic non-specific LBP will be recruited. Treatment sessions will be provided 3 times a week for 4 weeks (totaling 12 sessions) with patients receiving either placebo or active PBMT. For ethical reasons, all patients, regardless of treatment allocation, will also receive an information booklet based on "The Back Book". Clinical outcomes will be measured at baseline, at the end of treatment, as well as 3, 6, and 12 months after randomization. The primary outcomes will be pain intensity and disability measured after 12 sessions of treatment. The secondary outcomes will be pain intensity and disability measured at 3, 6, and 12 months after randomization, in addition to specific disability and global perceived effect in all time points. **Ethics and dissemination:** The study was approved by the Research Ethics Committee of Universidade Cidade de São Paulo. The results will be disseminated through scientific publications and presentations at national and international scientific meetings. Clinical trial registration number: NCT03089424 (clinicaltrials.gov).

Key-words: chronic low back pain, photobiomodulation therapy, low-level laser therapy, LLLT, PBMT.

Strengths and limitations of this study:

- The present study can be considered to have high methodological quality, since it is a randomized, controlled, and prospectively registered clinical trial.
- One of the strengths of the study is that it is triple-blinded, i.e., outcome assessors, therapists, and patients will be blinded to interventions over the course of the study.
- The sample size was calculated to provide the appropriate statistical power to detect precise differences for the primary outcomes of the study.

- 1
2
3 - In our study, we will test the effects of a single dose of PBMT (i.e 24 Joules). PBMT
4 is known to present a biphasic dose-response pattern, i.e., within a therapeutic
5 window (dosage range) the effects of biostimulation can be observed. However, if
6 dosages below or above this window are used, these effects may not be observed.
7
8 Therefore, the application of only one dose of PBMT may be considered a limitation
9 of this trial. However, in order to minimize this limitation, we based the choice of our
10 parameters using the best evidence available.
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

INTRODUCTION

Low back pain (LBP) is ranked as one of the most prevalent health problems and is highly associated with disability worldwide (1-4). It is estimated that about 12% of the world's population suffers from LBP (5). Furthermore, LBP generates high levels of work absenteeism and excessive costs to health systems (1, 2). The prognosis of LBP is directly related to the duration of symptoms, with less favorable prognoses in patients with chronic LBP (i.e. with a duration of symptoms longer than three months) (6-10). Therefore, the ideal treatment for chronic LBP represents a significant challenge, since there are no treatments that cure persistent LBP. However, several interventions provide low to moderate effects in reducing pain and disability on this population (11). The existing treatments for LBP can be divided into three categories: 1) pharmacological therapies, which trigger several adverse effects with prolonged use (12-14); 2) non-pharmacological therapies, which minimize undesirable effects and are moderately effective in LBP (15); and surgery, used only when conservative treatment is not efficacious (16). Several therapies can be used to treat LBP by controlling symptoms, minimizing disability, and improving the patients' quality of life (17).

Photobiomodulation therapy (PBMT) is a non-pharmacological intervention often used in the treatment of musculoskeletal disorders such as LBP (18-21). PBMT consists in applying a non-ionized form of light, which includes laser (light amplification by stimulated emission of radiation), LED (light-emitting diodes), and other lights with a broader spectrum ranging from visible to infrared (22). Recent evidence (23-28) suggests that PBMT triggers positive physiological effects, such as increased microcirculation (23), increased ATP synthesis (24, 25) stimulation of the mitochondrial respiratory chain (24, 25), stimulation of mitochondrial function (26), and factors that may influence the metabolism of various pathologies. In addition, there is evidence that PBMT reduces the release of both reactive oxygen species (ROS) and creatine kinase (CK) activity and also increases the production of antioxidants and heat shock proteins (27, 28).

As TFBM has been successfully proved as an effective intervention for neck pain patients (29); it is likely that TFBM could also be a reasonable option for patients with LBP. A range of previous trial have shown the effects of PBMT on acute, subacute and chronic LBP. Basford et al. (18) and Gur et al. (19) observed that PBMT appears to be effective in reducing pain and disability triggered by subacute and chronic LBP respectively. While Konstantinovic et al. (20) and Vallone et al. (21) found that PBMT combined with nonsteroidal anti-inflammatory drugs (NSAIDs) and exercise were efficient in reducing pain

1
2
3 intensity in patients with acute and chronic LBP respectively. In a recent systematic review,
4 Glazov et al. (30) found a clinically significant reduction in pain intensity in chronic LBP in
5 patients treated with PBMT, although a reliable conclusion was hindered by the high
6 heterogeneity in the parameters of therapy application. Furthermore, a recent clinical practice
7 guidelines (31) recommended the use of the PBMT as a possible nonpharmacological
8 treatment for chronic LBP. On the other hand, another trial (32) did not detected differences
9 between PBMT and placebo treatments on pain and disability in mixed sample of patients
10 with acute and chronic LBP associated with lumbar disk degeneration. These findings show
11 that there are still conflicts in the literature about PBMT in LBP. Therefore, high quality and
12 adequately powered trials are strongly needed.

13
14
15
16
17
18
19
20 Therefore, in spite of the positive results obtained in the aforementioned studies in
21 favor of PBMT, some factors warrant further investigation with high-quality studies on the
22 effects of PBMT applied in isolation in chronic non-specific LBP. Hence, it is necessary to
23 conduct a high quality, adequately powered, randomized placebo-controlled trial with
24 outcomes been measured at medium-and long-terms. Therefore, the objective of this study is
25 to evaluate the effects of PBMT against placebo in patients with chronic non-specific LBP in
26 the short, medium, and long term for the outcomes of pain intensity, general and specific
27 disability and global perceived effect.

33 34 35 **METHODS AND ANALYSES**

36 37 38 **Design**

39
40
41 A randomized, triple-blinded (patients, therapists, and outcome assessors), placebo-
42 controlled trial will be performed. The protocol of this study has been prospectively
43 registered on Clinicaltrials.gov (NCT03089424).

44 45 46 47 48 **Location**

49
50
51 The study will be conducted at the Center for Excellence in Clinical Research in
52 Physiotherapy of Universidade Cidade de São Paulo, Brazil.

53 54 55 56 57 **Eligibility criteria**

1
2
3 The study assessors will determine whether or not patients will be eligible to
4 participate in the study based on patient history and clinical examination.

5
6 Inclusion criteria:

- 7
8 - Patients with non-specific chronic LBP, defined as pain or discomfort between the
9 costal margins and inferior gluteal folds with or without referred pain to the lower
10 limbs;
11
12 - Persistent LBP for at least 3 months (33);
13
14 - Aged between 18 and 65 years;
15
16 - Both genders.

17
18 Exclusion criteria:

- 19
20 - Patients with severe skin diseases (e.g., skin cancer, erysipelas, severe eczema, severe
21 dermatitis, severe psoriasis and severe hives lupus);
22
23 - Patients with LBP associated with nerve root compromise (measured by clinical
24 examination of dermatomes, myotomes, and reflexes) (34, 35);
25
26 - Serious spinal pathologies such as fractures, tumors, inflammatory and infectious
27 diseases;
28
29 - Decompensated heart disease or metabolic disorders;
30
31 - Previous spinal surgery;
32
33 - Pregnancy.

34 35 36 **Interventions**

37
38
39 For ethical reasons, on the first day of treatment, all groups will receive an
40 information booklet on LBP called "The Back Book" (36) based on the recommendations of
41 the European Guidelines (35, 37). The booklet can be accessed freely via internet and it has
42 been translated into Portuguese by our research team. At each treatment session, patients will
43 receive further explanations on the contents of the booklet. There is consistent evidence that
44 *The Back Book* is useful for patients with LBP (38) and it has been used in clinical trials
45 conducted by our research group (39, 40).

46
47
48 Patients will then be randomly allocated to two groups to be submitted to the active
49 PBMT or Placebo interventions. The active and placebo PBMT will be performed using the
50 same device and the irradiated sites will be the same in both therapies. To ensure blinding for
51 therapists and patients, the device will emit the same sounds and the same information on the
52 display regardless of the programmed mode (active or placebo). Furthermore, because the
53
54
55
56
57
58
59
60

1
2
3 device produces a nonsignificant amount of heat (41), the patients will not be able to know if
4 active or placebo PBMT will be administered. The device was previously coded as active or
5 placebo modes, and only one researcher not involved in the randomization, treatment and
6 evaluation is aware of these codes. Patients will undergo treatment (active PBMT or
7 placebo), according to prior randomization, 3 times a week (with a minimal interval of 24
8 hours) for 4 consecutive weeks, totaling 12 therapy sessions. The choice of treatment
9 frequency was based on Basford et al. (18). The total treatment (active PBMT or placebo)
10 time will be 27 minutes per patient. The patients will be positioned preferably in prone.
11 However, in specific cases where patients do not tolerate this position due to pain, we will
12 respect the patient's preferred positioning. Intervention specifications:

13
14
15
16
17
18
19
20 1. Active PBMT Group: The PBMT will be performed using the Multi Radiance
21 Medical™ Super Pulsed Laser MR4™ console (Solon, OH, USA), with the SE25 (emitter
22 with an area of 4 cm²) and LaserShower (emitter with an area of 20 cm²) cluster probes as
23 emitters. Nine sites will be irradiated on the patient's lumbar region. PBMT irradiation sites
24 were chosen based on previous studies (18-21) and in order to cover the largest possible area
25 of the lumbar spine: 3 central sites on top of the spinous processes (between T11 and T12,
26 L2 and L3, L5 and S1), using the SE25 (3000 Hz of frequency, 3 minutes of irradiation per
27 site, 24.75 J per site, a totalizing 74.25 J irradiated from SE25); in the same direction, but
28 laterally, 3 sites on the left and 3 on the right (on the paravertebral muscles), using the
29 LaserShower (1000 Hz of frequency, 3 minutes of irradiation per site, 24.30 J per site, a total
30 of 145.80 J irradiated from LaserShower). At each treatment session, patients will receive a
31 total dose of 220.05 J. At the end of the 12 treatments sessions, patients will receive a total
32 dose of 2640.60 J. Table 1 shows parameters for SE25™ and LaserShower™ cluster probe.

33
34
35
36
37
38
39
40
41 This PBMT application protocol was based on the study of Leal Junior et al. (42).
42
43 Figure 1 shows the PBMT irradiation sites.
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1. Parameters for SE25™ and LaserShower™ cluster probe.

	SE25™	LaserShower™
Number of lasers	1 Super-pulsed infrared	4 Super-pulsed infrared
Wavelength (nm)	905 (±1)	905 (±1)
Frequency (Hz)	3000	1000
Peak power (W) - each	25	12.5
Average mean optical output (mW) - each	7.5	1.25
Power density (mW/cm ²) - each	17.05	2.84
Energy density (J/cm ²) - each	3.07	0.511
Dose (J) - each	1.35	0.225
Spot size of laser (cm ²) - each	0.44	0.44
Number of red LEDs	4 Red	4 Red
Wavelength of red LEDs (nm)	640 (±10)	640 (±10)
Frequency (Hz)	2	2
Average optical output (mW) - each	15	15
Power density (mW/cm ²) - each	16.67	16.67
Energy density (J/cm ²) - each	3	3
Dose (J) - each	2.7	2.7
Spot size of red LED (cm ²) - each	0.9	0.9
Number of infrared LEDs	4 Infrared	4 Infrared
Wavelength of infrared LEDs (nm)	875 (±10)	875 (±10)
Frequency (Hz)	16	16
Average optical output (mW) - each	17.5	17.5
Power density (mW/cm ²) - each	19.44	19.44
Energy density (J/cm ²) - each	3.5	3.5
Dose (J) - each	3.15	3.15
Spot Size of LED (cm ²) - each	0.9	0.9
Magnetic Field (mT)	35	35
Irradiation time per site (sec)	180	180
Total dose per site (J)	24.75	24.30
Aperture of device (cm ²)	4	20
Application mode	Cluster probe held stationary in skin contact with a 90-degree angle and slight pressure	Cluster probe held stationary in skin contact with a 90-degree angle and slight pressure

<< Figure 1 >>

2. Placebo PBMT Group: The placebo PBMT will be delivered using the same device that active PBMT, but without any emission of therapeutic dose. Patients will receive a total dose of 0 J in placebo mode. The placebo mode simulates the pragmatism of clinical practice and increases the credibility of the use of the equipment in relation to the treated

1
2
3 patients. The placebo technique has already been widely used in other studies with patients
4 with LBP (40, 43-48), as well as in studies using PBMT (41, 49, 50).
5

6 We will use two different emitters in PBMT (active or placebo) because we have
7 different objectives in each application area, which consequently require different
8 mechanisms of action. We will use the SE25 emitter on the spinous processes in order to
9 inhibit pain. Considering the smaller area of this emitter (4 cm²), the power density will be
10 increased, which will consequently induce the triggering of inhibitory effects, such as a
11 decrease in the axonal flow and thus analgesic effects (51, 52). In addition, the higher
12 frequency used in this emitter will also increase the number of photons that will reach the
13 target tissue, which will also promote the triggering of inhibitory effects and consequent
14 analgesic effect. For the erector spinae muscles, we will use the LaserShower 50 (LS50)
15 emitter in order to promote photobiostimulatory effects, considering the larger area of the
16 device (20 cm²), with consequent lower power density. In addition, this emitter has a lower
17 frequency, which will consequently decrease the number of photons delivered to the target
18 tissue. With these factors, we believe that we will promote an increase in the production of
19 ATP (24, 25), an increase in microcirculation (23) and consequently a decrease in muscle
20 fatigue and stiffness. This therapeutic strategy using different emitters and different
21 frequencies showed positive effects in the reduction of nonspecific knee pain in a previous
22 study that used this same PBMT device and these same emitters (42), however the
23 frequencies and doses were adapted for back pain patients.
24
25
26
27
28
29
30
31
32
33
34
35

36 The CONSORT flowchart summarizing experimental procedures and patients are
37 shown in figure 2.
38

39 << Figure 2 >>
40
41
42

43 **Outcomes**

44
45
46 Primary outcomes of the study will be obtained at baseline and immediately after the
47 last treatment session (4 weeks). Secondary outcomes of the study will be obtained at
48 baseline, at the end of treatment (4 weeks), and 3, 6, and 12 months after randomization.
49 These outcomes will be collected by an assessor who will not be aware of patient allocation
50 to their treatment groups.
51
52
53

54 The primary outcomes of the study will be:

- 55 - Pain intensity measured by the Pain Numerical Rating Scale (53). Pain Numerical
56 Rating Scale evaluates pain intensity levels perceived by the patient on an 11-point
57
58
59
60

1
2
3 scale ranging from 0 to 10, with 0 being "no pain" and 10 "the worst possible pain"
4 (53). Patients will be instructed to score the level of pain intensity based on the last 7
5 days.
6
7

- 8
9
10
11
12
13
14
15
16
17
- Disability associated with LBP, as measured by the Roland-Morris Disability Questionnaire (54, 55). The questionnaire consists of 24 items that describe situations that patients may have difficulty performing on a daily basis due to LBP. The greater the number of affirmative answers is, the higher the level of functional disability associated with LBP (53, 55). Patients will be instructed to answer according to their condition on the day of administration of the questionnaire.

18 The secondary outcomes of the study will be:

- 19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
- Specific disability, as measured by the Patient-Specific Functional Scale (53). The Patient-Specific Functional Scale is global and can be used for any part of the body. The measurement is done on an 11-point Likert scale for each activity, and the higher the average score is (ranging from 0 and 10 points), the better the patient's ability to perform the activities. The patients will be asked to identify up to three activities that they consider they are incapable of performing or that they have some difficulty performing (53, 56, 57).
 - Global perceived effect as measured by the Global Perceived Effect Scale (53). Global Perceived Effect Scale is an 11-point Likert scale, ranging from -5 to +5, that compares the patient's current condition to the onset of symptoms (53). Positive scores represent improvement, while the negative scores represent worsening in relation to the onset of symptoms. Values closer to 5 mean greater intensity of this perception (53).
 - Pain intensity measured by the Pain Numerical Rating Scale (53).
 - Disability associated with LBP, as measured by the Roland-Morris Disability Questionnaire (54, 55).

47 48 **Sample size**

49
50
51 The sample calculation of the study was performed to detect a 1-point difference for
52 the outcome pain intensity (as measured by the Pain Numerical Rating Scale) (53), with an
53 estimated standard deviation of 1.84 points and 4 points for the outcome disability associated
54 with LBP (measured by the Roland-Morris Disability Questionnaire) (54, 55), with an
55 estimated standard deviation of 4.9 points. A statistical power of 80% was considered for the
56
57
58
59
60

1
2
3 two outcomes, with α of 5% and a possible sample loss of up to 15%. Therefore, a total of
4 148 patients will be required for the study.
5
6
7

8 **Recruitment**

9
10
11 Patients seeking treatment for chronic LBP will be recruited at primary or secondary
12 care health services. We will partner with supervising clinicians at primary and secondary
13 health services so that they will refer chronic non-specific LBP patients to our study for
14 treatment.
15
16
17

18 **Randomization**

19
20
21 Prior to initiation of treatment, patients will be randomized into their respective
22 intervention groups. The randomization will be generated by a computer program (Excel
23 Office 2010) and performed by a participating researcher not involved with the recruitment
24 or evaluation of patients. This same researcher will be responsible for programming the
25 PBMT device according to the result of the randomization. The PBMT device used in the
26 present study will make the same sounds regardless of the programmed dose and mode
27 (active PBMT or placebo PBMT). This researcher will be instructed not to disclose the
28 programmed intervention to the therapist or any of the patients and other researchers
29 involved in the study until its completion. Patient and therapist will be blinded throughout
30 the treatment. Concealed allocation will be achieved through the use of sequentially
31 numbered, sealed, and opaque envelopes.
32
33
34
35
36
37
38
39
40
41

42 **Data collection**

43
44
45 The patients will be welcomed by the study's blinded assessor who will determine
46 whether they will be eligible to participate in the study. Subsequently, a file will be
47 completed with the patient's sociodemographic data and clinical history. Next, the primary
48 outcomes and the secondary outcomes of the study will be collected. Then, all eligible
49 patients will be randomized and allocated into two treatment groups: active PBMT or
50 placebo PBMT. At the end of the 12 treatment sessions, the primary and secondary outcomes
51 of the study participants will be reassessed by the same evaluator who performed the
52 baseline assessment. The 3, 6, and 12-month follow-ups will be performed by telephone by
53 the same evaluator who carried out the other evaluations. All of the questionnaires that will
54
55
56
57
58
59
60

1
2
3 be used in the present study have been fully tested for their measurement properties (53, 55).
4 These measurement properties were also tested over the phone. Therefore, we are confident
5 that the assessments are reliable.
6
7

8 9 **Statistical Analysis**

10
11
12 The statistical analysis will be conducted following the principles of intention-to-treat
13 analysis (58). The normality of the data will be tested by visual inspection of histograms and
14 the characterization of the participants will be calculated using descriptive statistical tests.
15 The between-group differences (treatment effects) and their respective 95% confidence
16 intervals will be calculated by using mixed linear models (59) using the group-by-time
17 interaction terms. The analyses will be performed using SPSS version 19.
18
19
20
21
22

23 24 **Ethics**

25
26
27 The present study was approved by the Research Ethics Committee of Universidade
28 Cidade de São Paulo (UNICID) under number 1.964.094. All patients eligible for the study
29 will be informed of the objectives and will be required to complete the Informed Consent
30 Form, as determined by Brazilian National Health Council Resolution 196/96.
31
32
33

34 35 **Dissemination**

36
37
38 The study will be disseminated through publication in peer-reviewed international
39 journals, as well as presentations at national and international conferences.
40
41
42

43 44 **Discussion**

45
46
47 Chronic LBP is a condition that is often associated with disability, emotional
48 alterations, and absenteeism from work (8). Since chronic LBP is very prevalent (11), it has
49 a great financial impact, generating high costs, both direct and indirect (60). This fact
50 demonstrates the importance of the constant investigation of more suitable treatments for
51 LBP, aiming at the well-being of the patient and the reduction of expenses for health
52 systems.
53
54
55
56
57
58
59
60

1
2
3 PBMT is one of the interventions recommended for the treatment of chronic LBP
4 (31), however, it is a relatively recent therapy given that the first clinical trial investigating
5 its effects on LBP was published in 1999 (18). Since then, there are still conflicts in the
6 literature about PBMT in LBP. Although there is evidence that PBMT is no better than
7 placebo treatment on pain and disability in a mixed sample of patients with acute and chronic
8 LBP (32), some studies have demonstrated the efficacy of PBMT in chronic and acute LBP
9 (18-21). Nevertheless, there are still issues to be clarified about its efficacy, as there are no
10 high-quality methodological studies that test PBMT versus placebo in LBP patients. To date,
11 studies evaluating the effects of PBMT on chronic non-specific LBP have not been
12 prospectively registered (18-21, 32); have a small sample size (18, 19, 21, 32) and have high
13 risk of bias. In addition, none of the studies were either triple blinded or were analyzed using
14 intention to treat principles.
15
16

17
18 It is extremely important to carry out studies with high methodological quality aimed
19 at contributing to a better understanding of the effects of PBMT on LBP. Only then will it be
20 possible to determine whether PBMT can be used as one of the treatments of choice for LBP.
21 If the effectiveness of PBMT in LBP is confirmed, it could be used as an alternative method
22 to NSAIDs or opioids, for example, since it causes similar or superior effects to these drugs,
23 shown in other chronic musculoskeletal disorders (61, 62), without the presence of known
24 adverse effects at present. We believe that, by providing relevant and compelling
25 information about PBMT, we will contribute to a safer and more effective clinical practice.
26
27

28
29 Nevertheless, it is important to highlight that PBMT presents a biphasic dose-
30 response pattern, i.e., within a therapeutic window (dose range) the biostimulation effects
31 can be seen. Very low doses may not trigger responses in the irradiated tissue, whereas very
32 high doses may cause inhibition (52). In addition, the power and time of irradiation are also
33 extremely important parameters to obtain better results with the PBMT (63). Therefore, the
34 choice of PBMT parameters is essential for obtaining positive results and represents an
35 important challenge in treating any musculoskeletal disorder. To date, there is great
36 heterogeneity in the parameters of PBMT used for the treatment of LBP, and it is not
37 possible to conclude the best dose for the treatment of this disorder. Thus, our parameters
38 were adapted from the best evidence available (42) and took into consideration the dosage
39 recommended by World Association for Laser Therapy (WALT) (63). Therefore, although
40 we believe that the dosage chosen for the present study is the most likely to be effective in
41 triggering the expected results, a limitation of our study is that we will test only one dose of
42 PBMT.
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 The present study can be considered to have high methodological quality, since it is a
4 randomized, controlled, and prospectively registered clinical trial. In addition, one of the
5 strengths of the study is that it is triple-blinded, i.e., evaluators, therapists, and patients will
6 be blinded to interventions over the course of the study. Finally, the sample size was
7 calculated to provide the appropriate statistical power to detect precise differences in the
8 primary outcomes of the study. Therefore, we believe that this study will contribute to the
9 evidence-based practice of PBMT in patients with chronic LBP.
10
11
12
13

14 15 **Author contributions**

16
17
18
19 SST and LOPC contributed to the concept and design of the study. SST and LOPC
20 established the hypothesis and wrote the original proposal. SST, LCMC, LSG, ACA, DPN,
21 FCM, MAA and LOPC contributed significantly in creating the manuscript. LCMC and
22 LOPC performed critical revisions of the manuscript. SST, LCMC and LOPC wrote the final
23 version of the manuscript. All authors read and approved the final version of the manuscript.
24
25
26
27

28 29 **Conflict of interest**

30 The authors declare no conflict of interest.
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

References:

1. Tulder MV. Chapter 1. European guidelines. *Eur Spine J* 2006;15:134-35.
2. American Academy Of Orthopaedic Surgeons. *US Bone and Joint Decade - The Burden of Musculoskeletal Diseases in the United States*. Rosemont, IL, USA, 2008.
3. Dagenais S, Caro J, Haldeman SA. systematic review of low back pain cost of illness studies in the United States and internationally. *Spine J*. 2008;8:8-20.
4. Murray CJ, Lopez AD. Measuring the global burden of disease. *N Engl J Med*. 2013;369:448-457.
5. Hoy D, Bain C, Williams G, March L, Brooks P, Blyth F, et al. A systematic review of the global prevalence of low back pain. *Arthritis Rheum*. 2012;64:2028-37.
6. Henschke N, Maher CG, Refshauge KM, Herbert RD, Cumming RG, Bleasel J, et al. Prognosis in patients with recent onset low back pain in Australian primary care: inception cohort study. *BMJ*. 2008;337:a171.
7. Costa Lda C, Maher CG, Mcauley JH, Hancock MJ, Herbert RD, Refshauge KM, et al. Prognosis for patients with chronic low back pain: inception cohort study. *BMJ*. 2009;339:b3829.
8. Da C Menezes Costa L, Maher CG, Hancock MJ, Mcauley JH, Herbert RD, Costa LO. The prognosis of acute and persistent low-back pain: a meta-analysis. *CMAJ*. 2012;184:E613-624.
9. Beattie PF, Silfies SP, Jordon M. The evolving role of physical therapists in the long-term management of chronic low back pain: longitudinal care using assisted self-management strategies. *Braz J Phys Ther* 2016;20:580-91.
10. Medeiros FC, Costa LO, Added MA, Salomão EC, Costa LD. Longitudinal Monitoring of Patients With Chronic Low Back Pain During Physical Therapy Treatment Using the STarT Back Screening Tool. *J Orthop Sports Phys Ther*. 2017;47:314-323.
11. Maher C, Underwood M, Buchbinder R. Non-specific low back pain. *Lancet*. 2017;389:736-47.
12. Bjordal JM, Ljunggren AE, Klovning A, Slørdal L. Non-steroidal anti-inflammatory drugs, including cyclo-oxygenase-2 inhibitors, in osteoarthritic knee pain: meta-analysis of randomised placebo controlled trials. *BMJ*. 2004;329:1317.
13. Chou R. Pharmacological management of low back pain. *Drugs*. 2010;70:387-402.
14. Dagenais S, Tricco AC, Haldeman S. Synthesis of recommendations for the assessment and management of low back pain from recent clinical practice guidelines. *Spine J*. 2010;10:514-29.
15. Van Middelkoop M, Rubinstein SM, Kuijpers T, Verhagen AP, Ostelo R, Koes BW, et

- 1
2
3 al. A systematic review on the effectiveness of physical and rehabilitation interventions for
4 chronic non-specific low back pain. *Eur Spine J.* 2011;20:19-39.
5
6
7 16. Bertagnoli R. Disc surgery in motion. *SpineLine.* 2004;5:23-28.
8
9 17. Sanders SH, Rucker KS, Anderson KO, Harden RN, Jackson KW, Vicente PJ, et al.
10 Clinical practice guidelines for chronic non-malignant pain syndrome patients. *J Back*
11 *Musculoskelet Rehabil.* 1995;5:115-20.
12
13 18. Basford JR, Sheffield CG, Harmsen WS. Laser therapy: a randomized, controlled trial of
14 the effects of low-intensity Nd:YAG laser irradiation on musculoskeletal back pain. *Arch*
15 *Phys Med Rehabil.* 1999;80:647-52.
16
17 19. Gur A, Karakoc M, Cevik R, Nas K, Sarac AJ, Karakoc M. Efficacy of low power laser
18 therapy and exercise on pain and functions in chronic low back pain. *Lasers Surg Med.*
19 2003;32:233-38.
20
21 20. Konstantinovic LM, Kanjuh ZM, Milovanovic AN, Cutovic MR, Djurovic AG, Savic
22 VG, et al. Acute low back pain with radiculopathy: a double-blind, randomized, placebo-
23 controlled study. *Photomed Laser Surg.* 2010;28:553-60.
24
25 21. Vallone F, Benedicenti S, Sorrenti E, Schiavetti I, Angiero F. Effect of diode laser in the
26 treatment of patients with nonspecific chronic low back pain: a randomized controlled trial.
27 *Photomed Laser Surg.* 2014;32:490-94.
28
29 22. Anders JJ, Lanzafame RJ, Arany PR. Low-level light/laser therapy versus
30 photobiomodulation therapy. *Photomed Laser Surg.* 2015;33:183-184.
31
32 23. Tullberg M, Alstergren PJ, Ernberg MM. Effects of low-power laser exposure on
33 masseter muscle pain and microcirculation. *Pain.* 2003;105:89-96.
34
35 24. Silveira PC, Silva LA, Fraga DB, Freitas TP, Streck EL, Pinho R. Evaluation of
36 mitochondrial respiratory chain activity in muscle healing by low-level laser therapy. *J*
37 *Photochem Photobiol B.* 2009;4:89-92
38
39 25. Albuquerque-Pontes GM, Vieira RP, Tomazoni SS, Caires CO, Nemeth V, Vanin AA, et
40 al. Effect of pre-irradiation with different doses, wavelengths, and application intervals of
41 low-level laser therapy on cytochrome c oxidase activity in intact skeletal muscle of rats.
42 *Lasers Med Sci.* 2015;30:59-66.
43
44 26. Xu X, Zhao X, Liu TC, Pan H. Low-intensity laser irradiation improves the
45 mitochondrial dysfunction of C2C12 induced by electrical stimulation. *Photomed Laser*
46 *Surg.* 2008;26:197-202.
47
48 27. Avni D, Levkovitz S, Maltz L, Oron U. Protection of skeletal muscles from ischemic
49 injury: low-level laser therapy increases antioxidant activity. *Photomed Laser Surg.*
50 2005;23:273-277.
51
52 28. Rizzi CF, Mauriz JL, Freitas Corrêa DS, Moreira AJ, Zettler CG, Filippin LI, et al.
53 Effects of low-level laser therapy (LLLT) on the nuclear factor (NF)-kappaB signaling
54
55
56
57
58
59
60

1
2
3 pathway in traumatized muscle. *Lasers Surg Med.* 2006;38:704-13.
4

5 29. Chow RT, Johnson MI, Lopes-Martins RA, Bjordal JM. Efficacy of low-level laser
6 therapy in the management of neck pain: a systematic review and meta-analysis of
7 randomised placebo or active-treatment controlled trials. *Lancet.* 2009;4:1897-908.
8

9
10 30. Glazov G, Yelland M, Emery J. Low-level laser therapy for chronic non-specific low
11 back pain: a meta-analysis of randomised controlled trials. *Acupunct Med.* 2016;34:328-341.
12

13 31. Qaseem A, Wilt TJ, McLean RM, Forcica MA. Clinical Guidelines Committee of the
14 American College of Physicians. Noninvasive Treatments for Acute, Subacute, and Chronic
15 Low Back Pain: A Clinical Practice Guideline From the American College of Physicians.
16 *Ann Intern Med.* 2017;166:514-530.
17

18 32. Ay S, Doğan SK, Evcik D. Is low-level laser therapy effective in acute or chronic low
19 back pain? *Clin Rheumatol.* 2010;29:905-10.
20

21
22 33. Airaksinen O, Brox JJ, Cedraschi C, Hildebrandt J, Klüber-Moffett J, Kovacs F, et al.
23 Chapter 4. European guidelines for the management of chronic nonspecific low back pain.
24 *Eur Spine J.* 2006;15Suppl2:192-300.
25

26 34. Magee, DJ. *Orthopedic Physical Assessment.* 6th Edition. Alberta, Canada: Elsevier
27 2008:569-618.
28

29
30 35. Delitto A, George SZ, Van Dillen L, Whitman JM, Sowa G, Shekelle P et al. Low Back
31 Pain. Clinical practice guidelines linked to the international classification of functioning,
32 disability, and health from the orthopaedic section of the American Physical Therapy
33 Association. *J Orthop Sports Phys Ther.* 2012;42:A1-A57.
34

35 36. Manchester MR, Glasgow GW, York JKM, Huddersfield KB, Salford CM, Southampton
36 TC. *The Back Book. Clinical Guidelines for the Management of Acute Low Back Pain.*
37 2002;1-28.
38

39
40 37. Van Tulder M, Becker A, Bekkering T, Breen A, Del Real MT, Hutchinson A, et al.
41 Chapter 3. European guidelines for the management of acute nonspecific low back pain in
42 primary care. *Eur Spine J.* 2006;15Suppl2:S169-191.
43

44 38. Engers A, Jellema P, Wensing M, Van Der Windt DA, Grol R, Van Tulder MW.
45 Individual patient education for low back pain. *Cochrane Database Syst Rev.*
46 2008;23:CD004057.
47

48 39. Garcia AN, Costa L Da C, Hancock MJ, De Almeida MO, De Souza FS, Costa LO.
49 Efficacy of the McKenzie method in patients with chronic nonspecific low back pain: a
50 protocol of randomized placebo-controlled trial. *Phys Ther.* 2015;95:267-273.
51

52
53 40. Garcia AN, Hancock M, Costa LCM, De Souza, FS, Gomes GVFO, Almeida MO, et al.
54 Efficacy of the mechanical diagnosis and therapy in patients with chronic nonspecific low
55 back pain: a randomized placebo controlled trial. 2017; *Brit J Sports Med* [in press]
56

57 41. Grandinetti V Dos S, Miranda EF, Johnson DS, De Paiva PR, Tomazoni SS, Vanin AA,
58
59
60

1
2
3 et al. The thermal impact of phototherapy with concurrent super-pulsed lasers and red and
4 infrared LEDs on human skin. *Lasers Med Sci.* 2015;30:1575-81.

5
6 42. Leal-Junior EC, Johnson DS, Saltmarche A, Demchak T. Adjunctive use of combination
7 of super-pulsed laser and light-emitting diodes phototherapy on nonspecific knee pain:
8 double-blinded randomized placebo-controlled trial. *Lasers Med Sci.* 2014;29:1839-47.

9
10 43. Costa LO, Maher CG, Latimer J, Hodges PW, Herbert RD, Refshauge KM.; et al. Motor
11 control exercise for chronic low back pain: a randomized placebo-controlled trial. *Phys Ther.*
12 2009;89:1275-86.

13
14 44. Kumar SP. Efficacy of segmental stabilization exercise for lumbar segmental instability
15 in patients with mechanical low back pain: A randomized placebo controlled crossover
16 study. *N Am J Med Sci.* 2011;3:456-461.

17
18 45. Ebadi S, Ansari NN, Naghdi S, Jalaei S, Sadat M, Bagheri H, et al. The effect of
19 continuous ultrasound on chronic non-specific low back pain: a single blind placebo-
20 controlled randomized trial. *BMC Musculoskelet Disord.* 2012;13:192.

21
22 46. Balthazard P, De Goumoens P, Rivier G, Demeulenaere P, Ballabeni P, Dériaz O.
23 Manual therapy followed by specific active exercises versus a placebo followed by specific
24 active exercises on the improvement of functional disability in patients with chronic non
25 specific low back pain: a randomized controlled trial. *BMC Musculoskelet Disord.*
26 2012;13:162.

27
28 47. Parreira Pdo C, Costa Lda C, Takahashi R, Hespanhol Junior LC, Luz Junior MA, Silva
29 TM, Costa LO. Kinesio taping to generate skin convolutions is not better than sham taping
30 for people with chronic non-specific low back pain: a randomised trial. *J Physiother.*
31 2014;60:90-6.

32
33 48. Luz Júnior MA, Sousa MV, Neves LA, Cezar AA, Costa LO. Kinesio Taping® is not
34 better than placebo in reducing pain and disability in patients with chronic non-specific low
35 back pain: a randomized controlled trial. *Braz J Phys Ther.* 2015;19:482-90.

36
37 49. Antonialli FC, De Marchi T, Tomazoni SS, Vanin AA, Dos Santos Grandinetti V, De
38 Paiva PR, et al. Phototherapy in skeletal muscle performance and recovery after exercise:
39 effect of combination of super-pulsed laser and light-emitting diodes. *Lasers Med Sci.*
40 2014;29:1967-76.

41
42 50. Miranda EF, De Oliveira LV, Antonialli FC, Vanin AA, De Carvalho PdeT, Leal-Junior
43 EC. Phototherapy with combination of super-pulsed laser and light-emitting diodes is
44 beneficial in improvement of muscular performance (strength and muscular endurance),
45 dyspnea, and fatigue sensation in patients with chronic obstructive pulmonary disease.
46 *Lasers Med Sci.* 2015;30:437-43.

47
48 51. Chow R, Armati P, Laakso EL, Bjordal JM, Baxter GD. Inhibitory effects of laser
49 irradiation on peripheral mammalian nerves and relevance to analgesic effects: a systematic
50 review. *Photomed Laser Surg.* 2011;29:365-81.

- 1
2
3 52. Huang YY, Sharma SK, Carrol J, Hamblin MR. Biphasic dose response in low level light
4 therapy – an update. *Dose Response*. 2011;9:602-618.
5
6 53. Costa LO, Maher CG, Latimer J, Ferreira PH, Ferreira ML, Pozzi GC, et al. Clinimetric
7 testing of three self-report outcome measures for low back pain patients in Brazil: which one
8 is the best? *Spine (Phila Pa 1976)*. 2008;33:2459-63.
9
10 54. Nusbaum L, Natour J, Ferraz MB, Goldenberg J. Translation, adaptation and validation
11 of the Roland-Morris questionnaire--Brazil Roland-Morris. *Braz J Med Biol Res*.
12 2001;34:203-210.
13
14 55. Costa LO, Maher CG, Latimer J, Ferreira PH, Pozzi GC, Ribeiro RN. Psychometric
15 characteristics of the Brazilian-Portuguese versions of the Functional Rating Index and the
16 Roland Morris Disability Questionnaire. *Spine (Phila Pa 1976)*. 2007;32:1902-07.
17
18 56. Chatman AB, Hyams SP, Neel JM, Binkley JM, Stratford PW, Schomberg A, et al. The
19 Patient-Specific Functional Scale: measurement properties in patients with knee dysfunction.
20 *Phys Ther*. 1997;77:820-29.
21
22 57. Pengel LH, Refshauge KM, Maher CG. Responsiveness of pain, disability, and physical
23 impairment outcomes in patients with low back pain. *Spine (Phila Pa 1976)*. 2004;29:879-83.
24
25 58. Elkins MR, Moseley AM. Intention-to-treat analysis. *J Physiother*. 2015;61:165-67.
26
27 59. Twisk JWR. *Applied Longitudinal Data Analysis for Epidemiology: A Practical Guide*
28 ISBN: 0521819768, 9780511061608; 2003.
29
30 60. Walker BF, Muller R, Grant WD. Low back pain in Australia adults: the economic
31 burden. *Asia Pac J Public Health*. 2003;15:79-87.
32
33 61. Tomazoni SS, Leal-Junior EC, Frigo L, Pallotta RC, Teixeira S, de Almeida P, et al.
34 Isolated and combined effects of photobiomodulation therapy, topical nonsteroidal anti-
35 inflammatory drugs, and physical activity in the treatment of osteoarthritis induced by
36 papain. *J Biomed Opt*. 2016;21:108001.
37
38 62. Tomazoni SS, Leal-Junior EC, Pallotta RC, Teixeira S, De Almeida P, Lopes-Martins
39 R.Á. Effects of photobiomodulation therapy, pharmacological therapy, and physical exercise
40 as single and/or combined treatment on the inflammatory response induced by experimental
41 osteoarthritis. *Lasers Med Sci*. 2017;32:101-108.
42
43 63. World Association for Laser Therapy - WALT (2010): Dosage recommendations.
44 Recommended treatment doses for low level laser therapy. Available in:
45 <http://www.walt.nu/dosage-recommendations.html>. Accessed May 30, 2017.
46
47
48
49
50

51 52 **FIGURE LEGENDS**

53
54 Table 1. Parameters for SE25™ and LaserShower™ cluster probe.
55
56

57
58 Figure 1. PBMT irradiation sites.
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure 2. Flow diagram of the study.

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



Figure 1. PBMT irradiation sites.
109x158mm (300 x 300 DPI)




Figure 2. Flow diagram of the study.

197x227mm (300 x 300 DPI)



SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents*

Section/item	Item No	Description	Page Number
Administrative information			
Title	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	1
Trial registration	2a	Trial identifier and registry name. If not yet registered, name of intended registry	1
	2b	All items from the World Health Organization Trial Registration Data Set	1
Protocol version	3	Date and version identifier	1
Funding	4	Sources and types of financial, material, and other support	1
Roles and responsibilities	5a	Names, affiliations, and roles of protocol contributors	1
	5b	Name and contact information for the trial sponsor	1
	5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	1
	5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)	1
Introduction			
Background and rationale	6a	Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention	4
	6b	Explanation for choice of comparators	7
Objectives	7	Specific objectives or hypotheses	5
Trial design	8	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory)	5

Methods: Participants, interventions, and outcomes

Study setting	9	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained	5
Eligibility criteria	10	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists)	5, 6
Interventions	11a	Interventions for each group with sufficient detail to allow replication, including how and when they will be administered	6, 7
	11b	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving/worsening disease)	6, 7
	11c	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return, laboratory tests)	6, 7
	11d	Relevant concomitant care and interventions that are permitted or prohibited during the trial	6, 7
Outcomes	12	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended	7, 8
Participant timeline	13	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure)	9
Sample size	14	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations	8, 9
Recruitment	15	Strategies for achieving adequate participant enrolment to reach target sample size	9

Methods: Assignment of interventions (for controlled trials)

Allocation:

Sequence generation	16a	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions	9
---------------------	-----	--	---

1				
2	Allocation	16b	Mechanism of implementing the allocation sequence (eg, central	9
3	concealment		telephone; sequentially numbered, opaque, sealed envelopes),	
4	mechanism		describing any steps to conceal the sequence until interventions are	
5			assigned	
6				
7	Implementation	16c	Who will generate the allocation sequence, who will enrol participants,	9
8			and who will assign participants to interventions	
9				
10	Blinding	17a	Who will be blinded after assignment to interventions (eg, trial	9
11	(masking)		participants, care providers, outcome assessors, data analysts), and	
12			how	
13				
14		17b	If blinded, circumstances under which unblinding is permissible, and	9
15			procedure for revealing a participant's allocated intervention during the	
16			trial	
17				
18				

Methods: Data collection, management, and analysis

19				
20				
21	Data collection	18a	Plans for assessment and collection of outcome, baseline, and other	8
22	methods		trial data, including any related processes to promote data quality (eg,	
23			duplicate measurements, training of assessors) and a description of	
24			study instruments (eg, questionnaires, laboratory tests) along with their	
25			reliability and validity, if known. Reference to where data collection	
26			forms can be found, if not in the protocol	
27				
28				
29		18b	Plans to promote participant retention and complete follow-up, including	9
30			list of any outcome data to be collected for participants who discontinue	
31			or deviate from intervention protocols	
32				
33	Data	19	Plans for data entry, coding, security, and storage, including any related	9
34	management		processes to promote data quality (eg, double data entry; range checks	
35			for data values). Reference to where details of data management	
36			procedures can be found, if not in the protocol	
37				
38				
39	Statistical	20a	Statistical methods for analysing primary and secondary outcomes.	10
40	methods		Reference to where other details of the statistical analysis plan can be	
41			found, if not in the protocol	
42				
43		20b	Methods for any additional analyses (eg, subgroup and adjusted	10
44			analyses)	
45				
46		20c	Definition of analysis population relating to protocol non-adherence (eg,	10
47			as randomised analysis), and any statistical methods to handle missing	
48			data (eg, multiple imputation)	
49				

Methods: Monitoring

50				
51				
52	Data monitoring	21a	Composition of data monitoring committee (DMC); summary of its role	-
53			and reporting structure; statement of whether it is independent from the	
54			sponsor and competing interests; and reference to where further details	
55			about its charter can be found, if not in the protocol. Alternatively, an	
56			explanation of why a DMC is not needed	
57				
58				
59				
60				

1		21b	Description of any interim analyses and stopping guidelines, including	-
2			who will have access to these interim results and make the final	
3			decision to terminate the trial	
4				
5				
6	Harms	22	Plans for collecting, assessing, reporting, and managing solicited and	-
7			spontaneously reported adverse events and other unintended effects of	
8			trial interventions or trial conduct	
9				
10	Auditing	23	Frequency and procedures for auditing trial conduct, if any, and	-
11			whether the process will be independent from investigators and the	
12			sponsor	
13				
14				
15	Ethics and dissemination			
16				
17	Research ethics approval	24	Plans for seeking research ethics committee/institutional review board	10
18			(REC/IRB) approval	
19				
20	Protocol amendments	25	Plans for communicating important protocol modifications (eg, changes	-
21			to eligibility criteria, outcomes, analyses) to relevant parties (eg,	
22			investigators, REC/IRBs, trial participants, trial registries, journals,	
23			regulators)	
24				
25	Consent or assent	26a	Who will obtain informed consent or assent from potential trial	10
26			participants or authorised surrogates, and how (see Item 32)	
27				
28		26b	Additional consent provisions for collection and use of participant data	-
29			and biological specimens in ancillary studies, if applicable	
30				
31	Confidentiality	27	How personal information about potential and enrolled participants will	10
32			be collected, shared, and maintained in order to protect confidentiality	
33			before, during, and after the trial	
34				
35				
36	Declaration of interests	28	Financial and other competing interests for principal investigators for	1
37			the overall trial and each study site	
38				
39	Access to data	29	Statement of who will have access to the final trial dataset, and	10
40			disclosure of contractual agreements that limit such access for	
41			investigators	
42				
43	Ancillary and post-trial care	30	Provisions, if any, for ancillary and post-trial care, and for compensation	-
44			to those who suffer harm from trial participation	
45				
46	Dissemination policy	31a	Plans for investigators and sponsor to communicate trial results to	10
47			participants, healthcare professionals, the public, and other relevant	
48			groups (eg, via publication, reporting in results databases, or other data	
49			sharing arrangements), including any publication restrictions	
50				
51				
52		31b	Authorship eligibility guidelines and any intended use of professional	-
53			writers	
54				
55		31c	Plans, if any, for granting public access to the full protocol, participant-	10
56			level dataset, and statistical code	
57				
58				
59				
60				

Appendices

Informed consent materials	32	Model consent form and other related documentation given to participants and authorised surrogates
Biological specimens	33	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable

*It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items. Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons "[Attribution-NonCommercial-NoDerivs 3.0 Unported](#)" license.

BMJ Open

Effects of photobiomodulation therapy in patients with chronic non-specific low back pain: protocol for a randomized placebo-controlled trial

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2017-017202.R2
Article Type:	Protocol
Date Submitted by the Author:	04-Aug-2017
Complete List of Authors:	Tomazoni, Shaiane; Universidade Cidade de Sao Paulo, Masters and Doctoral Programs in Physical Therapy Costa, Lucíola; Universidade Cidade de Sao Paulo, Masters and Doctoral Programs in Physical Therapy Guimarães, Layana; Universidade Cidade de Sao Paulo, Masters and Doctoral Programs in Physical Therapy Araujo, Amanda; Universidade Cidade de Sao Paulo, Masters and Doctoral Programs in Physical Therapy Nascimento, Dafne; Universidade Cidade de Sao Paulo, Masters and Doctoral Programs in Physical Therapy Medeiros, Flavia; Universidade Cidade de Sao Paulo, Masters and Doctoral Programs in Physical Therapy Avanzi, Marina; Universidade Cidade de Sao Paulo, Masters and Doctoral Programs in Physical Therapy Costa, Leonardo; Universidade Cidade de Sao Paulo, Masters and Doctoral Programs in Physical Therapy
Primary Subject Heading:	Evidence based practice
Secondary Subject Heading:	Rehabilitation medicine
Keywords:	chronic low back pain, photobiomodulation therapy, low-level laser therapy, LLLT, PBMT

SCHOLARONE™
Manuscripts

1
2
3 **Effects of photobiomodulation therapy in patients with chronic non-specific low back**
4 **pain: protocol for a randomized placebo-controlled trial**
5
6
7

8 Shaiane Silva Tomazoni^{1*}, Lucíola da Cunha Menezes Costa¹, Layana de Souza Guimarães¹,
9 Amanda Costa Araujo¹, Dafne Port Nascimento¹, Flávia Cordeiro de Medeiros¹, Marina
10 Athayde Avanzi¹ and Leonardo Oliveira Pena Costa¹
11
12

13
14
15 ¹. Masters and Doctoral Programs in Physical Therapy, Universidade Cidade de São Paulo,
16 Brazil.
17

18
19
20 **Trial registration number:** NCT03089424
21

22
23 **Funding statement:** This work was supported by FAPESP (postdoctoral scholarship of
24 Shaiane Silva Tomazoni) grant number 2016/10265-0.
25
26

27
28 **Roles of study sponsor and funders:** FAPESP has no role in study design; collection,
29 management, analysis, and interpretation of data; writing of the report; and the decision to submit the
30 report for publication, including whether they will have ultimate authority over any of these
31 activities.
32
33

34
35
36 ***Author for correspondence:** Shaiane Silva Tomazoni
37 Universidade Cidade de São Paulo. Rua Cesário Galeno, 448/475
38 Tatuapé, São Paulo, SP, Brazil, 05508-900.
39 e-mail: shaiane.tomazoni@gmail.com
40
41

42
43
44 **Number of figures and tables:** 2 figures and 1 table.
45
46

47 **Conflict of interest:** the authors declare no conflict of interest.
48
49
50
51
52
53
54
55
56
57
58
59
60

ABSTRACT

Introduction: Low back pain (LBP) is one of the largest and most frequent public health problems worldwide. Photobiomodulation therapy (PBMT) is a frequently used non-pharmacological therapy for the treatment of musculoskeletal disorders. However, there is little high-quality scientific evidence that demonstrates the effectiveness of PBMT in the treatment of patients with chronic LBP in the short, medium, and long term. Therefore, the objective of this clinical trial is to evaluate the effects of PBMT in patients with chronic non-specific LBP in the short, medium, and long term. **Methods and analyses:** This is a prospectively registered, two-arm randomized placebo-controlled trial with blinded patients, assessors and treatment providers. One hundred and forty-eight patients with chronic non-specific LBP will be recruited. Treatment sessions will be provided 3 times a week for 4 weeks (totaling 12 sessions) with patients receiving either placebo or active PBMT. For ethical reasons, all patients, regardless of treatment allocation, will also receive an information booklet based on "The Back Book". Clinical outcomes will be measured at baseline, at the end of treatment, as well as 3, 6, and 12 months after randomization. The primary outcomes will be pain intensity and disability measured after 12 sessions of treatment. The secondary outcomes will be pain intensity and disability measured at 3, 6, and 12 months after randomization, in addition to specific disability and global perceived effect in all time points. **Ethics and dissemination:** The study was approved by the Research Ethics Committee of Universidade Cidade de São Paulo. The results will be disseminated through scientific publications and presentations at national and international scientific meetings. Clinical trial registration number: NCT03089424 (clinicaltrials.gov).

Key-words: chronic low back pain, photobiomodulation therapy, low-level laser therapy, LLLT, PBMT.

Strengths and limitations of this study:

- The present study can be considered to have high methodological quality, since it is a randomized, controlled, and prospectively registered clinical trial.
- One of the strengths of the study is that it is triple-blinded, i.e., outcome assessors, therapists, and patients will be blinded to interventions over the course of the study.
- The sample size was calculated to provide the appropriate statistical power to detect precise differences for the primary outcomes of the study.

- 1
2
3 - In our study, we will test the effects of a single dose of PBMT (i.e 24 Joules). PBMT
4 is known to present a biphasic dose-response pattern, i.e., within a therapeutic
5 window (dosage range) the effects of biostimulation can be observed. However, if
6 dosages below or above this window are used, these effects may not be observed.
7
8 Therefore, the application of only one dose of PBMT may be considered a limitation
9 of this trial. However, in order to minimize this limitation, we based the choice of our
10 parameters using the best available evidence.
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

INTRODUCTION

Low back pain (LBP) is ranked as one of the most prevalent health problems and is highly associated with disability worldwide (1-4). It is estimated that about 12% of the world's population suffers from LBP (5). Furthermore, LBP generates high levels of work absenteeism and excessive costs to health systems (1, 2). The prognosis of LBP is directly related to the duration of symptoms, with less favorable prognoses in patients with chronic LBP (i.e. with a duration of symptoms longer than three months) (6-10). Therefore, the ideal treatment for chronic LBP represents a significant challenge, since there are no treatments that cure persistent LBP. However, several interventions provide low to moderate effects in reducing pain and disability on this population (11). The existing treatments for LBP can be divided into three categories: 1) pharmacological therapies, which trigger several adverse effects with prolonged use (12-14); 2) non-pharmacological therapies, which minimize undesirable effects and are moderately effective in LBP (15); and surgery, used only when conservative treatment is not efficacious (16). Several therapies can be used to treat LBP by controlling symptoms, minimizing disability, and improving the patients' quality of life (17).

Photobiomodulation therapy (PBMT) is a non-pharmacological intervention often used in the treatment of musculoskeletal disorders such as LBP (18-21). PBMT consists in applying a non-ionized form of light, which includes laser (light amplification by stimulated emission of radiation), LED (light-emitting diodes), and other lights with a broader spectrum ranging from visible to infrared (22). Recent evidence (23-28) suggests that PBMT triggers positive physiological effects, such as increased microcirculation (23), increased ATP synthesis (24, 25) stimulation of the mitochondrial respiratory chain (24, 25), stimulation of mitochondrial function (26), and factors that may influence the metabolism of various pathologies. In addition, there is evidence that PBMT reduces the release of both reactive oxygen species (ROS) and creatine kinase (CK) activity and also increases the production of antioxidants and heat shock proteins (27, 28).

As PBMT has been successfully proved as an effective intervention for neck pain patients (29); it is likely that PBMT could also be a reasonable option for patients with LBP. A range of previous trial have shown the effects of PBMT on acute, subacute and chronic LBP. Basford et al. (18) and Gur et al. (19) observed that PBMT appears to be effective in reducing pain and disability triggered by subacute and chronic LBP respectively. While Konstantinovic et al. (20) and Vallone et al. (21) found that PBMT combined with nonsteroidal anti-inflammatory drugs (NSAIDs) and exercise were efficient in reducing pain

1
2
3 intensity in patients with acute and chronic LBP respectively. In a recent systematic review,
4 Glazov et al. (30) found a clinically significant reduction in pain intensity in chronic LBP in
5 patients treated with PBMT, although a reliable conclusion was hindered by the high
6 heterogeneity in the parameters of therapy application. Furthermore, a recent clinical practice
7 guidelines (31) recommended the use of the PBMT as a possible nonpharmacological
8 treatment for chronic LBP. On the other hand, another trial (32) did not detected differences
9 between PBMT and placebo treatments on pain and disability in mixed sample of patients
10 with acute and chronic LBP associated with lumbar disk degeneration. These findings show
11 that there are still conflicts in the literature about PBMT in LBP. Therefore, high quality and
12 adequately powered trials are strongly needed.

13
14
15
16
17
18
19
20 Therefore, in spite of the positive results obtained in the aforementioned studies in
21 favor of PBMT, some factors warrant further investigation with high-quality studies on the
22 effects of PBMT applied in isolation in chronic non-specific LBP. Hence, it is necessary to
23 conduct a high quality, adequately powered, randomized placebo-controlled trial with
24 outcomes been measured at medium-and long-terms. Therefore, the objective of this study is
25 to evaluate the effects of PBMT against placebo in patients with chronic non-specific LBP in
26 the short, medium, and long term for the outcomes of pain intensity, general and specific
27 disability and global perceived effect.

33 34 35 **METHODS AND ANALYSES**

36 37 38 **Design**

39
40
41 A randomized, triple-blinded (patients, therapists, and outcome assessors), placebo-
42 controlled trial will be performed. The protocol of this study has been prospectively
43 registered on Clinicaltrials.gov (NCT03089424).

44 45 46 47 48 **Study setting**

49
50
51 The study will be conducted at the Center for Excellence in Clinical Research in
52 Physiotherapy of Universidade Cidade de São Paulo, Brazil.

53 54 55 56 57 **Eligibility criteria**

1
2
3 The study assessors will determine whether or not patients will be eligible to
4 participate in the study based on patient history and clinical examination.

5
6 Inclusion criteria:

- 7
8 - Patients with non-specific chronic LBP, defined as pain or discomfort between the
9 costal margins and inferior gluteal folds with or without referred pain to the lower
10 limbs;
11
12 - Persistent LBP for at least 3 months (33);
13
14 - Aged between 18 and 65 years;
15
16 - Both genders.

17
18 Exclusion criteria:

- 19
20 - Patients with severe skin diseases (e.g., skin cancer, erysipelas, severe eczema, severe
21 dermatitis, severe psoriasis and severe hives lupus);
22
23 - Patients with LBP associated with nerve root compromise (measured by clinical
24 examination of dermatomes, myotomes, and reflexes) (34, 35);
25
26 - Serious spinal pathologies such as fractures, tumors, inflammatory and infectious
27 diseases;
28
29 - Decompensated heart disease or metabolic disorders;
30
31 - Previous spinal surgery;
32
33 - Pregnancy.

34 35 36 **Interventions**

37
38
39 For ethical reasons, on the first day of treatment, all groups will receive an
40 information booklet on LBP called "The Back Book" (36) based on the recommendations of
41 the European Guidelines (35, 37). The booklet can be accessed freely via internet and it has
42 been translated into Portuguese by our research team. At each treatment session, patients will
43 receive further explanations on the contents of the booklet. There is consistent evidence that
44 *The Back Book* is useful for patients with LBP (38) and it has been used in clinical trials
45 conducted by our research group (39, 40).

46
47
48 Patients will then be randomly allocated to two groups to be submitted to the active
49 PBMT or Placebo interventions. The active and placebo PBMT will be performed using the
50 same device and the irradiated sites will be the same in both therapies. To ensure blinding for
51 therapists and patients, the device will emit the same sounds and the same information on the
52 display regardless of the programmed mode (active or placebo). Furthermore, because the
53
54
55
56
57
58
59
60

1
2
3 device produces a nonsignificant amount of heat (41), the patients will not be able to know if
4 active or placebo PBMT will be administered. The device was previously coded as active or
5 placebo modes, and only one researcher not involved in the randomization, treatment and
6 evaluation is aware of these codes. Patients will undergo treatment (active PBMT or
7 placebo), according to prior randomization, 3 times a week (with a minimal interval of 24
8 hours) for 4 consecutive weeks, totaling 12 therapy sessions. The choice of treatment
9 frequency was based on Basford et al. (18). The total treatment (active PBMT or placebo)
10 time will be 27 minutes per patient. The patients will be positioned preferably in prone.
11 However, in specific cases where patients do not tolerate this position due to pain, we will
12 respect the patient's preferred positioning. Intervention specifications:

13
14
15
16
17
18
19
20 1. Active PBMT Group: The PBMT will be performed using the Multi Radiance
21 Medical™ Super Pulsed Laser MR4™ console (Solon, OH, USA), with the SE25 (emitter
22 with an area of 4 cm²) and LaserShower (emitter with an area of 20 cm²) cluster probes as
23 emitters. Nine sites will be irradiated on the patient's lumbar region. PBMT irradiation sites
24 were chosen based on previous studies (18-21) and in order to cover the largest possible area
25 of the lumbar spine: 3 central sites on top of the spinous processes (between T11 and T12,
26 L2 and L3, L5 and S1), using the SE25 (3000 Hz of frequency, 3 minutes of irradiation per
27 site, 24.75 J per site, a totalizing 74.25 J irradiated from SE25); in the same direction, but
28 laterally, 3 sites on the left and 3 on the right (on the paravertebral muscles), using the
29 LaserShower (1000 Hz of frequency, 3 minutes of irradiation per site, 24.30 J per site, a total
30 of 145.80 J irradiated from LaserShower). At each treatment session, patients will receive a
31 total dose of 220.05 J. At the end of the 12 treatments sessions, patients will receive a total
32 dose of 2640.60 J. Table 1 shows parameters for SE25™ and LaserShower™ cluster probe.

33
34
35
36
37
38
39
40
41 This PBMT application protocol was based on the study of Leal Junior et al. (42).
42
43 Figure 1 shows the PBMT irradiation sites.
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1. Parameters for SE25™ and LaserShower™ cluster probe.

	SE25™	LaserShower™
Number of lasers	1 Super-pulsed infrared	4 Super-pulsed infrared
Wavelength (nm)	905 (±1)	905 (±1)
Frequency (Hz)	3000	1000
Peak power (W) - each	25	12.5
Average mean optical output (mW) - each	7.5	1.25
Power density (mW/cm ²) - each	17.05	2.84
Energy density (J/cm ²) - each	3.07	0.511
Dose (J) - each	1.35	0.225
Spot size of laser (cm ²) - each	0.44	0.44
Number of red LEDs	4 Red	4 Red
Wavelength of red LEDs (nm)	640 (±10)	640 (±10)
Frequency (Hz)	2	2
Average optical output (mW) - each	15	15
Power density (mW/cm ²) - each	16.67	16.67
Energy density (J/cm ²) - each	3	3
Dose (J) - each	2.7	2.7
Spot size of red LED (cm ²) - each	0.9	0.9
Number of infrared LEDs	4 Infrared	4 Infrared
Wavelength of infrared LEDs (nm)	875 (±10)	875 (±10)
Frequency (Hz)	16	16
Average optical output (mW) - each	17.5	17.5
Power density (mW/cm ²) - each	19.44	19.44
Energy density (J/cm ²) - each	3.5	3.5
Dose (J) - each	3.15	3.15
Spot Size of LED (cm ²) - each	0.9	0.9
Magnetic Field (mT)	35	35
Irradiation time per site (sec)	180	180
Total dose per site (J)	24.75	24.30
Aperture of device (cm ²)	4	20
Application mode	Cluster probe held stationary in skin contact with a 90-degree angle and slight pressure	Cluster probe held stationary in skin contact with a 90-degree angle and slight pressure

<< Figure 1 >>

2. Placebo PBMT Group: The placebo PBMT will be delivered using the same device that active PBMT, but without any emission of therapeutic dose. Patients will receive a total dose of 0 J in placebo mode. The placebo mode simulates the pragmatism of clinical practice and increases the credibility of the use of the equipment in relation to the treated

1
2
3 patients. The placebo technique has already been widely used in other studies with patients
4 with LBP (40, 43-48), as well as in studies using PBMT (41, 49, 50).

5
6 We will use two different emitters in PBMT (active or placebo) because we have
7 different objectives in each application area, which consequently require different
8 mechanisms of action. We will use the SE25 emitter on the spinous processes in order to
9 inhibit pain. Considering the smaller area of this emitter (4 cm²), the power density will be
10 increased, which will consequently induce the triggering of inhibitory effects, such as a
11 decrease in the axonal flow and thus analgesic effects (51, 52). In addition, the higher
12 frequency used in this emitter will also increase the number of photons that will reach the
13 target tissue, which will also promote the triggering of inhibitory effects and consequent
14 analgesic effect. For the erector spinae muscles, we will use the LaserShower 50 (LS50)
15 emitter in order to promote photobiostimulatory effects, considering the larger area of the
16 device (20 cm²), with consequent lower power density. In addition, this emitter has a lower
17 frequency, which will consequently decrease the number of photons delivered to the target
18 tissue. With these factors, we believe that we will promote an increase in the production of
19 ATP (24, 25), an increase in microcirculation (23) and consequently a decrease in muscle
20 fatigue and stiffness. This therapeutic strategy using different emitters and different
21 frequencies showed positive effects in the reduction of nonspecific knee pain in a previous
22 study that used this same PBMT device and these same emitters (42), however the
23 frequencies and doses were adapted for back pain patients.
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39

40 **Outcomes and blinding**

41
42
43 Primary outcomes of the study will be obtained at baseline and immediately after the
44 last treatment session (4 weeks). Secondary outcomes of the study will be obtained at
45 baseline, at the end of treatment (4 weeks), and 3, 6, and 12 months after randomization.
46 These outcomes will be collected by an assessor who will not be aware of patient allocation
47 to their treatment groups.
48
49
50

51 The primary outcomes of the study will be:

- 52 - Pain intensity measured by the Pain Numerical Rating Scale (53). Pain Numerical
53 Rating Scale evaluates pain intensity levels perceived by the patient on an 11-point
54 scale ranging from 0 to 10, with 0 being "no pain" and 10 "the worst possible pain"
55
56
57
58
59
60

(53). Patients will be instructed to score the level of pain intensity based on the last 7 days.

- Disability associated with LBP, as measured by the Roland-Morris Disability Questionnaire (54, 55). The questionnaire consists of 24 items that describe situations that patients may have difficulty performing on a daily basis due to LBP. The greater the number of affirmative answers is, the higher the level of functional disability associated with LBP (53, 55). Patients will be instructed to answer according to their condition on the day of administration of the questionnaire.

The secondary outcomes of the study will be:

- Specific disability, as measured by the Patient-Specific Functional Scale (53). The Patient-Specific Functional Scale is global and can be used for any part of the body. The measurement is done on an 11-point Likert scale for each activity, and the higher the average score is (ranging from 0 and 10 points), the better the patient's ability to perform the activities. The patients will be asked to identify up to three activities that they consider they are incapable of performing or that they have some difficulty performing (53, 56, 57).
- Global perceived effect as measured by the Global Perceived Effect Scale (53). Global Perceived Effect Scale is an 11-point Likert scale, ranging from -5 to +5, that compares the patient's current condition to the onset of symptoms (53). Positive scores represent improvement, while the negative scores represent worsening in relation to the onset of symptoms. Values closer to 5 mean greater intensity of this perception (53).
- Pain intensity measured by the Pain Numerical Rating Scale (53).
- Disability associated with LBP, as measured by the Roland-Morris Disability Questionnaire (54, 55).

Participant timeline

The CONSORT flowchart summarizing experimental procedures and patients are shown in figure 2.

<< Figure 2 >>

Sample size

The sample calculation of the study was performed to detect a 1-point difference for the outcome pain intensity (as measured by the Pain Numerical Rating Scale) (53), with an estimated standard deviation of 1.84 points and 4 points for the outcome disability associated with LBP (measured by the Roland-Morris Disability Questionnaire) (54, 55), with an estimated standard deviation of 4.9 points. A statistical power of 80% was considered for the two outcomes, with α of 5% and a possible sample loss of up to 15%. Therefore, a total of 148 patients will be required for the study.

Recruitment

Patients seeking treatment for chronic LBP will be recruited at primary or secondary care health services. We will partner with supervising clinicians at primary and secondary health services so that they will refer chronic non-specific LBP patients to our study for treatment.

Randomization

Prior to initiation of treatment, patients will be randomized into their respective intervention groups. The randomization will be generated by a computer program (Excel Office 2010) and performed by a participating researcher not involved with the recruitment or evaluation of patients. This same researcher will be responsible for programming the PBMT device according to the result of the randomization. The PBMT device used in the present study will make the same sounds regardless of the programmed dose and mode (active PBMT or placebo PBMT). This researcher will be instructed not to disclose the programmed intervention to the therapist or any of the patients and other researchers involved in the study until its completion. Patient and therapist will be blinded throughout the treatment. Concealed allocation will be achieved through the use of sequentially numbered, sealed, and opaque envelopes.

Data collection

The patients will be welcomed by the study's blinded assessor who will determine whether they will be eligible to participate in the study. Subsequently, a file will be

1
2
3 completed with the patient's sociodemographic data and clinical history. Next, the primary
4 outcomes and the secondary outcomes of the study will be collected. Then, all eligible
5 patients will be randomized and allocated into two treatment groups: active PBMT or
6 placebo PBMT. At the end of the 12 treatment sessions, the primary and secondary outcomes
7 of the study participants will be reassessed by the same evaluator who performed the
8 baseline assessment. The 3, 6, and 12-month follow-ups will be performed by telephone by
9 the same evaluator who carried out the other evaluations. All of the questionnaires that will
10 be used in the present study have been fully tested for their measurement properties (53, 55).
11 These measurement properties were also tested over the phone. Therefore, we are confident
12 that the assessments are reliable.
13
14
15
16
17
18
19

20 21 **Statistical Analysis**

22
23
24 The statistical analysis will be conducted following the principles of intention-to-treat
25 analysis (58). The normality of the data will be tested by visual inspection of histograms and
26 the characterization of the participants will be calculated using descriptive statistical tests.
27 The between-group differences (treatment effects) and their respective 95% confidence
28 intervals will be calculated by using mixed linear models (59) using the group-by-time
29 interaction terms. The analyses will be performed using SPSS version 19.
30
31
32
33
34

35 **Ethics**

36
37
38 The present study was approved by the Research Ethics Committee of Universidade
39 Cidade de São Paulo (UNICID) under number 1.964.094. All patients eligible for the study
40 will be informed by study assessors of the objectives and will be required to complete the
41 Informed Consent Form (appendix 1), as determined by Brazilian National Health Council
42 Resolution 196/96.
43
44
45
46

47 Research personnel will take all appropriate and customary steps to ensure that data
48 remain secure and that patient privacy and confidentiality will be maintained.
49
50

51 **Dissemination Policy**

52
53
54
55 The study will be disseminated through publication in peer-reviewed international
56 journals, as well as presentations at national and international conferences.
57
58
59
60

Discussion

Chronic LBP is a condition that is often associated with disability, emotional alterations, and absenteeism from work (8). Since chronic LBP is very prevalent (11), it has a great financial impact, generating high costs, both direct and indirect (60). This fact demonstrates the importance of the constant investigation of more suitable treatments for LBP, aiming at the well-being of the patient and the reduction of expenses for health systems.

PBMT is one of the interventions recommended for the treatment of chronic LBP (31), however, it is a relatively recent therapy given that the first clinical trial investigating its effects on LBP was published in 1999 (18). Since then, there are still conflicts in the literature about PBMT in LBP. Although there is evidence that PBMT is no better than placebo treatment on pain and disability in a mixed sample of patients with acute and chronic LBP (32), some studies have demonstrated the efficacy of PBMT in chronic and acute LBP (18-21). Nevertheless, there are still issues to be clarified about its efficacy, as there are no high-quality methodological studies that test PBMT versus placebo in LBP patients. To date, studies evaluating the effects of PBMT on chronic non-specific LBP have not been prospectively registered (18-21, 32); have a small sample size (18, 19, 21, 32) and have high risk of bias. In addition, none of the studies were either triple blinded or were analyzed using intention to treat principles.

It is extremely important to carry out studies with high methodological quality aimed at contributing to a better understanding of the effects of PBMT on LBP. Only then will it be possible to determine whether PBMT can be used as one of the treatments of choice for LBP. If the effectiveness of PBMT in LBP is confirmed, it could be used as an alternative method to NSAIDs or opioids, for example, since it causes similar or superior effects to these drugs, shown in other chronic musculoskeletal disorders (61, 62), without the presence of known adverse effects at present. We believe that, by providing relevant and compelling information about PBMT, we will contribute to a safer and more effective clinical practice.

Nevertheless, it is important to highlight that PBMT presents a biphasic dose-response pattern, i.e., within a therapeutic window (dose range) the biostimulation effects can be seen. Very low doses may not trigger responses in the irradiated tissue, whereas very high doses may cause inhibition (52). In addition, the power and time of irradiation are also extremely important parameters to obtain better results with the PBMT (63). Therefore, the

1
2
3 choice of PBMT parameters is essential for obtaining positive results and represents an
4 important challenge in treating any musculoskeletal disorder. To date, there is great
5 heterogeneity in the parameters of PBMT used for the treatment of LBP, and it is not
6 possible to conclude the best dose for the treatment of this disorder. Thus, our parameters
7 were adapted from the best evidence available (42) and took into consideration the dosage
8 recommended by World Association for Laser Therapy (WALT) (63). Therefore, although
9 we believe that the dosage chosen for the present study is the most likely to be effective in
10 triggering the expected results, a limitation of our study is that we will test only one dose of
11 PBMT.
12

13
14
15
16
17
18 The present study can be considered to have high methodological quality, since it is a
19 randomized, controlled, and prospectively registered clinical trial. In addition, one of the
20 strengths of the study is that it is triple-blinded, i.e., evaluators, therapists, and patients will
21 be blinded to interventions over the course of the study. Finally, the sample size was
22 calculated to provide the appropriate statistical power to detect precise differences in the
23 primary outcomes of the study. Therefore, we believe that this study will contribute to the
24 evidence-based practice of PBMT in patients with chronic LBP.
25
26
27
28
29

30 31 **Author contributions**

32
33
34 SST and LOPC contributed to the concept and design of the study. SST and LOPC
35 established the hypothesis and wrote the original proposal. SST, LCMC, LSG, ACA, DPN,
36 FCM, MAA and LOPC contributed significantly in the development of the manuscript.
37 LCMC and LOPC performed critical revisions of the manuscript. SST, LCMC and LOPC
38 wrote the final version of the manuscript. All authors read and approved the final version of
39 the manuscript.
40
41
42
43
44

45 46 **Conflict of interest**

47 The authors declare no conflict of interest.
48
49
50
51
52
53
54
55
56
57
58
59
60

References:

1. Tulder MV. Chapter 1. European guidelines. *Eur Spine J* 2006;15:134-35.
2. American Academy Of Orthopaedic Surgeons. *US Bone and Joint Decade - The Burden of Musculoskeletal Diseases in the United States*. Rosemont, IL, USA, 2008.
3. Dagenais S, Caro J, Haldeman SA. systematic review of low back pain cost of illness studies in the United States and internationally. *Spine J*. 2008;8:8-20.
4. Murray CJ, Lopez AD. Measuring the global burden of disease. *N Engl J Med*. 2013;369:448-457.
5. Hoy D, Bain C, Williams G, March L, Brooks P, Blyth F, et al. A systematic review of the global prevalence of low back pain. *Arthritis Rheum*. 2012;64:2028-37.
6. Henschke N, Maher CG, Refshauge KM, Herbert RD, Cumming RG, Bleasel J, et al. Prognosis in patients with recent onset low back pain in Australian primary care: inception cohort study. *BMJ*. 2008;337:a171.
7. Costa Lda C, Maher CG, Mcauley JH, Hancock MJ, Herbert RD, Refshauge KM, et al. Prognosis for patients with chronic low back pain: inception cohort study. *BMJ*. 2009;339:b3829.
8. Da C Menezes Costa L, Maher CG, Hancock MJ, Mcauley JH, Herbert RD, Costa LO. The prognosis of acute and persistent low-back pain: a meta-analysis. *CMAJ*. 2012;184:E613-624.
9. Beattie PF, Silfies SP, Jordon M. The evolving role of physical therapists in the long-term management of chronic low back pain: longitudinal care using assisted self-management strategies. *Braz J Phys Ther* 2016;20:580-91.
10. Medeiros FC, Costa LO, Added MA, Salomão EC, Costa LD. Longitudinal Monitoring of Patients With Chronic Low Back Pain During Physical Therapy Treatment Using the STarT Back Screening Tool. *J Orthop Sports Phys Ther*. 2017;47:314-323.
11. Maher C, Underwood M, Buchbinder R. Non-specific low back pain. *Lancet*. 2017;389:736-47.
12. Bjordal JM, Ljunggren AE, Klovning A, Slørdal L. Non-steroidal anti-inflammatory drugs, including cyclo-oxygenase-2 inhibitors, in osteoarthritic knee pain: meta-analysis of randomised placebo controlled trials. *BMJ*. 2004;329:1317.
13. Chou R. Pharmacological management of low back pain. *Drugs*. 2010;70:387-402.
14. Dagenais S, Tricco AC, Haldeman S. Synthesis of recommendations for the assessment and management of low back pain from recent clinical practice guidelines. *Spine J*. 2010;10:514-29.
15. Van Middelkoop M, Rubinstein SM, Kuijpers T, Verhagen AP, Ostelo R, Koes BW, et

- 1
2
3 al. A systematic review on the effectiveness of physical and rehabilitation interventions for
4 chronic non-specific low back pain. *Eur Spine J.* 2011;20:19-39.
5
6
7 16. Bertagnoli R. Disc surgery in motion. *SpineLine.* 2004;5:23-28.
8
9 17. Sanders SH, Rucker KS, Anderson KO, Harden RN, Jackson KW, Vicente PJ, et al.
10 Clinical practice guidelines for chronic non-malignant pain syndrome patients. *J Back*
11 *Musculoskelet Rehabil.* 1995;5:115-20.
12
13 18. Basford JR, Sheffield CG, Harmsen WS. Laser therapy: a randomized, controlled trial of
14 the effects of low-intensity Nd:YAG laser irradiation on musculoskeletal back pain. *Arch*
15 *Phys Med Rehabil.* 1999;80:647-52.
16
17 19. Gur A, Karakoc M, Cevik R, Nas K, Sarac AJ, Karakoc M. Efficacy of low power laser
18 therapy and exercise on pain and functions in chronic low back pain. *Lasers Surg Med.*
19 2003;32:233-38.
20
21 20. Konstantinovic LM, Kanjuh ZM, Milovanovic AN, Cutovic MR, Djurovic AG, Savic
22 VG, et al. Acute low back pain with radiculopathy: a double-blind, randomized, placebo-
23 controlled study. *Photomed Laser Surg.* 2010;28:553-60.
24
25 21. Vallone F, Benedicenti S, Sorrenti E, Schiavetti I, Angiero F. Effect of diode laser in the
26 treatment of patients with nonspecific chronic low back pain: a randomized controlled trial.
27 *Photomed Laser Surg.* 2014;32:490-94.
28
29 22. Anders JJ, Lanzafame RJ, Arany PR. Low-level light/laser therapy versus
30 photobiomodulation therapy. *Photomed Laser Surg.* 2015;33:183-184.
31
32 23. Tullberg M, Alstergren PJ, Ernberg MM. Effects of low-power laser exposure on
33 masseter muscle pain and microcirculation. *Pain.* 2003;105:89-96.
34
35 24. Silveira PC, Silva LA, Fraga DB, Freitas TP, Streck EL, Pinho R. Evaluation of
36 mitochondrial respiratory chain activity in muscle healing by low-level laser therapy. *J*
37 *Photochem Photobiol B.* 2009;4:89-92
38
39 25. Albuquerque-Pontes GM, Vieira RP, Tomazoni SS, Caires CO, Nemeth V, Vanin AA, et
40 al. Effect of pre-irradiation with different doses, wavelengths, and application intervals of
41 low-level laser therapy on cytochrome c oxidase activity in intact skeletal muscle of rats.
42 *Lasers Med Sci.* 2015;30:59-66.
43
44 26. Xu X, Zhao X, Liu TC, Pan H. Low-intensity laser irradiation improves the
45 mitochondrial dysfunction of C2C12 induced by electrical stimulation. *Photomed Laser*
46 *Surg.* 2008;26:197-202.
47
48 27. Avni D, Levkovitz S, Maltz L, Oron U. Protection of skeletal muscles from ischemic
49 injury: low-level laser therapy increases antioxidant activity. *Photomed Laser Surg.*
50 2005;23:273-277.
51
52 28. Rizzi CF, Mauriz JL, Freitas Corrêa DS, Moreira AJ, Zettler CG, Filippin LI, et al.
53 Effects of low-level laser therapy (LLLT) on the nuclear factor (NF)-kappaB signaling
54
55
56
57
58
59
60

1
2
3 pathway in traumatized muscle. *Lasers Surg Med.* 2006;38:704-13.
4

5 29. Chow RT, Johnson MI, Lopes-Martins RA, Bjordal JM. Efficacy of low-level laser
6 therapy in the management of neck pain: a systematic review and meta-analysis of
7 randomised placebo or active-treatment controlled trials. *Lancet.* 2009;4:1897-908.
8

9
10 30. Glazov G, Yelland M, Emery J. Low-level laser therapy for chronic non-specific low
11 back pain: a meta-analysis of randomised controlled trials. *Acupunct Med.* 2016;34:328-341.
12

13 31. Qaseem A, Wilt TJ, McLean RM, Forcica MA. Clinical Guidelines Committee of the
14 American College of Physicians. Noninvasive Treatments for Acute, Subacute, and Chronic
15 Low Back Pain: A Clinical Practice Guideline From the American College of Physicians.
16 *Ann Intern Med.* 2017;166:514-530.
17

18 32. Ay S, Doğan SK, Evcik D. Is low-level laser therapy effective in acute or chronic low
19 back pain? *Clin Rheumatol.* 2010;29:905-10.
20

21
22 33. Airaksinen O, Brox JJ, Cedraschi C, Hildebrandt J, Klüber-Moffett J, Kovacs F, et al.
23 Chapter 4. European guidelines for the management of chronic nonspecific low back pain.
24 *Eur Spine J.* 2006;15Suppl2:192-300.
25

26 34. Magee, DJ. *Orthopedic Physical Assessment.* 6th Edition. Alberta, Canada: Elsevier
27 2008:569-618.
28

29
30 35. Delitto A, George SZ, Van Dillen L, Whitman JM, Sowa G, Shekelle P et al. Low Back
31 Pain. Clinical practice guidelines linked to the international classification of functioning,
32 disability, and health from the orthopaedic section of the American Physical Therapy
33 Association. *J Orthop Sports Phys Ther.* 2012;42:A1-A57.
34

35 36. Manchester MR, Glasgow GW, York JKM, Huddersfield KB, Salford CM, Southampton
36 TC. *The Back Book. Clinical Guidelines for the Management of Acute Low Back Pain.*
37 2002;1-28.
38

39
40 37. Van Tulder M, Becker A, Bekkering T, Breen A, Del Real MT, Hutchinson A, et al.
41 Chapter 3. European guidelines for the management of acute nonspecific low back pain in
42 primary care. *Eur Spine J.* 2006;15Suppl2:S169-191.
43

44 38. Engers A, Jellema P, Wensing M, Van Der Windt DA, Grol R, Van Tulder MW.
45 Individual patient education for low back pain. *Cochrane Database Syst Rev.*
46 2008;23:CD004057.
47

48 39. Garcia AN, Costa L Da C, Hancock MJ, De Almeida MO, De Souza FS, Costa LO.
49 Efficacy of the McKenzie method in patients with chronic nonspecific low back pain: a
50 protocol of randomized placebo-controlled trial. *Phys Ther.* 2015;95:267-273.
51

52
53 40. Garcia AN, Hancock M, Costa LCM, De Souza, FS, Gomes GVFO, Almeida MO, et al.
54 Efficacy of the mechanical diagnosis and therapy in patients with chronic nonspecific low
55 back pain: a randomized placebo controlled trial. 2017; *Brit J Sports Med* [in press]
56 doi: 10.1136/bjsports-2016-097327
57
58
59
60

- 1
2
3
4 41. Grandinetti V, Dos S, Miranda EF, Johnson DS, De Paiva PR, Tomazoni SS, Vanin AA,
5 et al. The thermal impact of phototherapy with concurrent super-pulsed lasers and red and
6 infrared LEDs on human skin. *Lasers Med Sci.* 2015;30:1575-81.
7
8
9 42. Leal-Junior EC, Johnson DS, Saltmarche A, Demchak T. Adjunctive use of combination
10 of super-pulsed laser and light-emitting diodes phototherapy on nonspecific knee pain:
11 double-blinded randomized placebo-controlled trial. *Lasers Med Sci.* 2014;29:1839-47.
12
13 43. Costa LO, Maher CG, Latimer J, Hodges PW, Herbert RD, Refshauge KM.; et al. Motor
14 control exercise for chronic low back pain: a randomized placebo-controlled trial. *Phys Ther.*
15 2009;89:1275-86.
16
17 44. Kumar SP. Efficacy of segmental stabilization exercise for lumbar segmental instability
18 in patients with mechanical low back pain: A randomized placebo controlled crossover
19 study. *N Am J Med Sci.* 2011;3:456-461.
20
21 45. Ebadi S, Ansari NN, Naghdi S, Jalaei S, Sadat M, Bagheri H, et al. The effect of
22 continuous ultrasound on chronic non-specific low back pain: a single blind placebo-
23 controlled randomized trial. *BMC Musculoskelet Disord.* 2012;13:192.
24
25 46. Balthazard P, De Goumoens P, Rivier G, Demeulenaere P, Ballabeni P, Dériaz O.
26 Manual therapy followed by specific active exercises versus a placebo followed by specific
27 active exercises on the improvement of functional disability in patients with chronic non
28 specific low back pain: a randomized controlled trial. *BMC Musculoskelet Disord.*
29 2012;13:162.
30
31 47. Parreira Pdo C, Costa Lda C, Takahashi R, Hespanhol Junior LC, Luz Junior MA, Silva
32 TM, Costa LO. Kinesio taping to generate skin convolutions is not better than sham taping
33 for people with chronic non-specific low back pain: a randomised trial. *J Physiother.*
34 2014;60:90-6.
35
36 48. Luz Júnior MA, Sousa MV, Neves LA, Cezar AA, Costa LO. Kinesio Taping® is not
37 better than placebo in reducing pain and disability in patients with chronic non-specific low
38 back pain: a randomized controlled trial. *Braz J Phys Ther.* 2015;19:482-90.
39
40 49. Antonialli FC, De Marchi T, Tomazoni SS, Vanin AA, Dos Santos Grandinetti V, De
41 Paiva PR, et al. Phototherapy in skeletal muscle performance and recovery after exercise:
42 effect of combination of super-pulsed laser and light-emitting diodes. *Lasers Med Sci.*
43 2014;29:1967-76.
44
45 50. Miranda EF, De Oliveira LV, Antonialli FC, Vanin AA, De Carvalho PdeT, Leal-Junior
46 EC. Phototherapy with combination of super-pulsed laser and light-emitting diodes is
47 beneficial in improvement of muscular performance (strength and muscular endurance),
48 dyspnea, and fatigue sensation in patients with chronic obstructive pulmonary disease.
49 *Lasers Med Sci.* 2015;30:437-43.
50
51 51. Chow R, Armati P, Laakso EL, Bjordal JM, Baxter GD. Inhibitory effects of laser
52 irradiation on peripheral mammalian nerves and relevance to analgesic effects: a systematic
53 review. *Photomed Laser Surg.* 2011;29:365-81.
54
55
56
57
58
59
60

- 1
2
3
4 52. Huang YY, Sharma SK, Carrol J, Hamblin MR. Biphasic dose response in low level light
5 therapy – an update. *Dose Response*. 2011;9:602-618.
6
7
8 53. Costa LO, Maher CG, Latimer J, Ferreira PH, Ferreira ML, Pozzi GC, et al. Clinimetric
9 testing of three self-report outcome measures for low back pain patients in Brazil: which one
10 is the best? *Spine (Phila Pa 1976)*. 2008;33:2459-63.
11
12 54. Nusbaum L, Natour J, Ferraz MB, Goldenberg J. Translation, adaptation and validation
13 of the Roland-Morris questionnaire--Brazil Roland-Morris. *Braz J Med Biol Res*.
14 2001;34:203-210.
15
16 55. Costa LO, Maher CG, Latimer J, Ferreira PH, Pozzi GC, Ribeiro RN. Psychometric
17 characteristics of the Brazilian-Portuguese versions of the Functional Rating Index and the
18 Roland Morris Disability Questionnaire. *Spine (Phila Pa 1976)*. 2007;32:1902-07.
19
20
21 56. Chatman AB, Hyams SP, Neel JM, Binkley JM, Stratford PW, Schomberg A, et al. The
22 Patient-Specific Functional Scale: measurement properties in patients with knee dysfunction.
23 *Phys Ther*. 1997;77:820-29.
24
25 57. Pengel LH, Refshauge KM, Maher CG. Responsiveness of pain, disability, and physical
26 impairment outcomes in patients with low back pain. *Spine (Phila Pa 1976)*. 2004;29:879-83.
27
28
29 58. Elkins MR, Moseley AM. Intention-to-treat analysis. *J Physiother*. 2015;61:165-67.
30
31 59. Twisk JWR. *Applied Longitudinal Data Analysis for Epidemiology: A Practical Guide*
32 ISBN: 0521819768, 9780511061608; 2003.
33
34 60. Walker BF, Muller R, Grant WD. Low back pain in Australia adults: the economic
35 burden. *Asia Pac J Public Health*. 2003;15:79-87.
36
37 61. Tomazoni SS, Leal-Junior EC, Frigo L, Pallotta RC, Teixeira S, de Almeida P, et al.
38 Isolated and combined effects of photobiomodulation therapy, topical nonsteroidal anti-
39 inflammatory drugs, and physical activity in the treatment of osteoarthritis induced by
40 papain. *J Biomed Opt*. 2016;21:108001.
41
42 62. Tomazoni SS, Leal-Junior EC, Pallotta RC, Teixeira S, De Almeida P, Lopes-Martins
43 R.Á. Effects of photobiomodulation therapy, pharmacological therapy, and physical exercise
44 as single and/or combined treatment on the inflammatory response induced by experimental
45 osteoarthritis. *Lasers Med Sci*. 2017;32:101-108.
46
47 63. World Association for Laser Therapy - WALT (2010): Dosage recommendations.
48 Recommended treatment doses for low level laser therapy. Available in:
49 <http://www.walt.nu/dosage-recommendations.html>. Accessed May 30, 2017.
50
51
52

53 FIGURE LEGENDS

54
55
56 Table 1. Parameters for SE25™ and LaserShower™ cluster probe.
57
58
59
60

1
2
3 Figure 1. PBMT irradiation sites.
4
5

6 Figure 2. Flow diagram of the study.
7
8

9 Appendix 1. Model consent form
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



Figure 1. PBMT irradiation sites.
109x158mm (300 x 300 DPI)




Figure 2. Flow diagram of the study.

197x227mm (300 x 300 DPI)

Informed Consent Form

To Mr./Mrs. _____
ID no. _____, born in _____,
gender _____, home address _____

You have been invited to participate in the study titled: *"Effects of photobiomodulation therapy in patients with chronic non-specific low back pain: a randomized placebo-controlled trial"*. This trial aims to evaluate the efficacy of photobiomodulation therapy (PBMT) in patients with non-specific chronic low back. In order to participate, you will be firstly screened by one of the researchers, who will determine if you are eligible for the study. If so, you will you respond a number of scales and questionnaires that measure intensity of your low back pain, disability, and impression of recovery since the onset of your symptoms. At the initial assessment, you will be asked to perform some movements of your spine and some tests will be carried out to better understand your clinical condition. You may feel some discomfort during and after the assessment, which tends to improve in the short term. The researchers involved in this study will take all necessary care to minimize these possible discomforts. After the assessment, you will be randomly allocated to two possible interventions: 1) active PBMT (therapy with a light with special properties capable of penetrating the tissues of your body and triggering therapeutic effects) or 2) placebo PBMT (therapy with a light having special properties capable of penetrating the tissues of your body and triggering therapeutic effects, applied at a very low dose below the therapeutic dose). You will not be able to identify which intervention you will be receiving. For safety reasons, during the application of the therapies, you must wear special, dark, protective goggles that will block the passage of light. This equipment will be provided by the therapist. Wearing these glasses will protect your eyes from direct contact with the light, thus avoiding possible damage to your eyesight. If you feel any discomfort during therapy, please notify the therapist and request immediate interruption of the application. In addition, regardless of the group to which you will be allocated, you will also receive an information booklet designed specifically for patients with low back pain (there are several studies that demonstrate the effectiveness of this booklet in patients with low back pain). In addition, you will be free to clarify any questions at each session with your therapist. The treatment will last 12 sessions (3 sessions weekly, for 4 weeks,

1
2
3 lasting 30 minutes each). After the end of treatment, you will be reassessed by the same
4 therapist who evaluated you initially. This therapist will contact you at 3, 6, and 12
5 months after the beginning of the treatment to measure your symptoms.
6
7

8
9 Any clarifications can be provided by the chief investigator, Leonardo Oliveira Pena
10 Costa, at Rua Cesário Galeno, 448, Tatuapé or via telephone on (11) 2178-1564.
11

12 We guarantee the confidentiality of all the information collected and you may withdraw
13 your consent at any time, without any penalty or loss of benefit.
14
15

16
17 I hereby attest that I have been informed and fully understand the objectives of this study,
18 the techniques and procedures I will receive, and the risks and discomforts that may occur.
19 I have received guarantee of total confidentiality and of obtaining further clarification
20 whenever I wish. Therefore, I agree to voluntarily participate in this study and I
21 understand that I may withdraw my consent at any time without any penalty or loss of
22 benefit (if the subject is enrolled in the Institution where the research is being conducted).
23
24
25
26
27
28
29

30 Date: __ / __ / __
31
32

33
34 _____
35 Signature of study participant or legal representative
36
37
38

39 _____
40 **Chief investigator**
41
42

43 I, Leonardo Oliveira Pena Costa, chief investigator of the study "*Effects of*
44 "*photobiomodulation therapy in patients with chronic non-specific low back pain: a*
45 "*randomized placebo-controlled trial*" hereby declare that I have obtained the free consent
46 of this study participant (or his or her legal representative) to conduct this study.
47
48
49
50

51
52
53 Date: __ / __ / ____
54
55
56
57

58 _____
59 Signature of the chief investigator
60



SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents*

Section/item	Item No	Description	Page Number
Administrative information			
Title	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	1
Trial registration	2a	Trial identifier and registry name. If not yet registered, name of intended registry	1
	2b	All items from the World Health Organization Trial Registration Data Set	1
Protocol version	3	Date and version identifier	1
Funding	4	Sources and types of financial, material, and other support	1
Roles and responsibilities	5a	Names, affiliations, and roles of protocol contributors	1
	5b	Name and contact information for the trial sponsor	1
	5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	1
	5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)	1
Introduction			
Background and rationale	6a	Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention	4
	6b	Explanation for choice of comparators	5
Objectives	7	Specific objectives or hypotheses	5
Trial design	8	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory)	5

Methods: Participants, interventions, and outcomes

Study setting	9	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained	5
Eligibility criteria	10	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists)	6
Interventions	11a	Interventions for each group with sufficient detail to allow replication, including how and when they will be administered	6, 7
	11b	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving/worsening disease)	6, 7
	11c	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return, laboratory tests)	6
	11d	Relevant concomitant care and interventions that are permitted or prohibited during the trial	6, 7
Outcomes	12	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended	9, 10
Participant timeline	13	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure)	9
Sample size	14	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations	10
Recruitment	15	Strategies for achieving adequate participant enrolment to reach target sample size	11

Methods: Assignment of interventions (for controlled trials)

Allocation:

Sequence generation	16a	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions	11
---------------------	-----	--	----

1				
2	Allocation	16b	Mechanism of implementing the allocation sequence (eg, central	11
3	concealment		telephone; sequentially numbered, opaque, sealed envelopes),	
4	mechanism		describing any steps to conceal the sequence until interventions are	
5			assigned	
6				
7	Implementation	16c	Who will generate the allocation sequence, who will enrol participants,	11
8			and who will assign participants to interventions	
9				
10	Blinding	17a	Who will be blinded after assignment to interventions (eg, trial	11
11	(masking)		participants, care providers, outcome assessors, data analysts), and	
12			how	
13				
14		17b	If blinded, circumstances under which unblinding is permissible, and	11
15			procedure for revealing a participant's allocated intervention during the	
16			trial	
17				
18				
19	Methods: Data collection, management, and analysis			
20				
21	Data collection	18a	Plans for assessment and collection of outcome, baseline, and other	9, 10
22	methods		trial data, including any related processes to promote data quality (eg,	
23			duplicate measurements, training of assessors) and a description of	
24			study instruments (eg, questionnaires, laboratory tests) along with their	
25			reliability and validity, if known. Reference to where data collection	
26			forms can be found, if not in the protocol	
27				
28				
29		18b	Plans to promote participant retention and complete follow-up, including	11, 12
30			list of any outcome data to be collected for participants who discontinue	
31			or deviate from intervention protocols	
32				
33	Data	19	Plans for data entry, coding, security, and storage, including any related	11, 12
34	management		processes to promote data quality (eg, double data entry; range checks	
35			for data values). Reference to where details of data management	
36			procedures can be found, if not in the protocol	
37				
38				
39	Statistical	20a	Statistical methods for analysing primary and secondary outcomes.	12
40	methods		Reference to where other details of the statistical analysis plan can be	
41			found, if not in the protocol	
42				
43		20b	Methods for any additional analyses (eg, subgroup and adjusted	-
44			analyses)	
45				
46		20c	Definition of analysis population relating to protocol non-adherence (eg,	12
47			as randomised analysis), and any statistical methods to handle missing	
48			data (eg, multiple imputation)	
49				
50	Methods: Monitoring			
51				
52	Data monitoring	21a	Composition of data monitoring committee (DMC); summary of its role	-
53			and reporting structure; statement of whether it is independent from the	
54			sponsor and competing interests; and reference to where further details	
55			about its charter can be found, if not in the protocol. Alternatively, an	
56			explanation of why a DMC is not needed	
57				
58				
59				
60				

1		21b	Description of any interim analyses and stopping guidelines, including	-
2			who will have access to these interim results and make the final	
3			decision to terminate the trial	
4				
5				
6	Harms	22	Plans for collecting, assessing, reporting, and managing solicited and	-
7			spontaneously reported adverse events and other unintended effects of	
8			trial interventions or trial conduct	
9				
10	Auditing	23	Frequency and procedures for auditing trial conduct, if any, and	-
11			whether the process will be independent from investigators and the	
12			sponsor	
13				
14				
15	Ethics and dissemination			
16				
17	Research ethics approval	24	Plans for seeking research ethics committee/institutional review board	12
18			(REC/IRB) approval	
19				
20	Protocol amendments	25	Plans for communicating important protocol modifications (eg, changes	-
21			to eligibility criteria, outcomes, analyses) to relevant parties (eg,	
22			investigators, REC/IRBs, trial participants, trial registries, journals,	
23			regulators)	
24				
25	Consent or assent	26a	Who will obtain informed consent or assent from potential trial	12
26			participants or authorised surrogates, and how (see Item 32)	
27				
28		26b	Additional consent provisions for collection and use of participant data	-
29			and biological specimens in ancillary studies, if applicable	
30				
31	Confidentiality	27	How personal information about potential and enrolled participants will	12
32			be collected, shared, and maintained in order to protect confidentiality	
33			before, during, and after the trial	
34				
35				
36	Declaration of interests	28	Financial and other competing interests for principal investigators for	1
37			the overall trial and each study site	
38				
39	Access to data	29	Statement of who will have access to the final trial dataset, and	10
40			disclosure of contractual agreements that limit such access for	
41			investigators	
42				
43	Ancillary and post-trial care	30	Provisions, if any, for ancillary and post-trial care, and for compensation	-
44			to those who suffer harm from trial participation	
45				
46	Dissemination policy	31a	Plans for investigators and sponsor to communicate trial results to	12
47			participants, healthcare professionals, the public, and other relevant	
48			groups (eg, via publication, reporting in results databases, or other data	
49			sharing arrangements), including any publication restrictions	
50				
51				
52		31b	Authorship eligibility guidelines and any intended use of professional	-
53			writers	
54				
55		31c	Plans, if any, for granting public access to the full protocol, participant-	-
56			level dataset, and statistical code	
57				
58				
59				
60				

Appendices

Informed consent materials	32	Model consent form and other related documentation given to participants and authorised surrogates
Biological specimens	33	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable

*It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items. Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons "[Attribution-NonCommercial-NoDerivs 3.0 Unported](#)" license.